A therapeutic approach, involving chemotherapy, radiation therapy, or surgery, after initial regimens have failed to lead to improvement in a patient's condition. Salvage therapy is most often used for neoplastic diseases.
An alternative to amputation in patients with neoplasms, ischemia, fractures, and other limb-threatening conditions. Generally, sophisticated surgical procedures such as vascular surgery and reconstruction are used to salvage diseased limbs.
The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form.
Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.
A malignant disease characterized by progressive enlargement of the lymph nodes, spleen, and general lymphoid tissue. In the classical variant, giant usually multinucleate Hodgkin's and REED-STERNBERG CELLS are present; in the nodular lymphocyte predominant variant, lymphocytic and histiocytic cells are seen.
Therapeutic act or process that initiates a response to a complete or partial remission level.
A measure of the quality of health care by assessment of unsuccessful results of management and procedures used in combating disease, in individual cases or series.
The return of a sign, symptom, or disease after a remission.
Positional isomer of CYCLOPHOSPHAMIDE which is active as an alkylating agent and an immunosuppressive agent.
The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used.
A semisynthetic derivative of PODOPHYLLOTOXIN that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.
Transplantation of an individual's own tissue from one site to another site.
The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site.
A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472)
Tissue ablation of the PROSTATE performed by ultrasound from a transducer placed in the RECTUM. The procedure is used to treat prostate cancer (PROSTATIC NEOPLASMS) and benign prostatic hypertrophy (PROSTATIC HYPERPLASIA).
Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons.
Period after successful treatment in which there is no appearance of the symptoms or effects of the disease.
A malignant neoplasm of the germinal tissue of the GONADS; MEDIASTINUM; or pineal region. Germinomas are uniform in appearance, consisting of large, round cells with vesicular nuclei and clear or finely granular eosinophilic-staining cytoplasm. (Stedman, 265th ed; from DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, pp1642-3)
A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
The proportion of survivors in a group, e.g., of patients, studied and followed over a period, or the proportion of persons in a specified group alive at the beginning of a time interval who survive to the end of the interval. It is often studied using life table methods.
Any of a group of malignant tumors of lymphoid tissue that differ from HODGKIN DISEASE, being more heterogeneous with respect to malignant cell lineage, clinical course, prognosis, and therapy. The only common feature among these tumors is the absence of giant REED-STERNBERG CELLS, a characteristic of Hodgkin's disease.
A class of statistical procedures for estimating the survival function (function of time, starting with a population 100% well at a given time and providing the percentage of the population still well at later times). The survival analysis is then used for making inferences about the effects of treatments, prognostic factors, exposures, and other covariates on the function.
Transfer of HEMATOPOIETIC STEM CELLS from BONE MARROW or BLOOD between individuals within the same species (TRANSPLANTATION, HOMOLOGOUS) or transfer within the same individual (TRANSPLANTATION, AUTOLOGOUS). Hematopoietic stem cell transplantation has been used as an alternative to BONE MARROW TRANSPLANTATION in the treatment of a variety of neoplasms.
Vomiting caused by expectation of discomfort or unpleasantness.
Antibodies obtained from a single clone of cells grown in mice or rats.
A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations.
A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed)
An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle.
Antitumor alkaloid isolated from Vinca rosea. (Merck, 11th ed.)
Infections with fungi of the genus ASPERGILLUS.
A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY.
Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience.
Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease.
Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.
Partial or total surgical excision of the tongue. (Dorland, 28th ed)
The transfer of STEM CELLS from one individual to another within the same species (TRANSPLANTATION, HOMOLOGOUS) or between species (XENOTRANSPLANTATION), or transfer within the same individual (TRANSPLANTATION, AUTOLOGOUS). The source and location of the stem cells determines their potency or pluripotency to differentiate into various cell types.
Recovery of blood lost from surgical procedures for reuse by the same patient in AUTOLOGOUS BLOOD TRANSFUSIONS. It is collected during (intraoperatively) or after completion of (postoperatively) the surgical procedures.
An anti-inflammatory 9-fluoro-glucocorticoid.
An alkylating nitrogen mustard that is used as an antineoplastic in the form of the levo isomer - MELPHALAN, the racemic mixture - MERPHALAN, and the dextro isomer - MEDPHALAN; toxic to bone marrow, but little vesicant action; potential carcinogen.
The ability of viruses to resist or to become tolerant to chemotherapeutic agents or antiviral agents. This resistance is acquired through gene mutation.
A lignan (LIGNANS) found in PODOPHYLLIN resin from the roots of PODOPHYLLUM plants. It is a potent spindle poison, toxic if taken internally, and has been used as a cathartic. It is very irritating to skin and mucous membranes, has keratolytic actions, has been used to treat warts and keratoses, and may have antineoplastic properties, as do some of its congeners and derivatives.
Infection in humans and animals caused by fungi in the class Zygomycetes. It includes MUCORMYCOSIS and entomophthoramycosis. The latter is a tropical infection of subcutaneous tissue or paranasal sinuses caused by fungi in the order Entomophthorales. Phycomycosis, closely related to zygomycosis, describes infection with members of Phycomycetes, an obsolete classification.
Ester of CHLORAMBUCIL and PREDNISOLONE used as a combination alkylating agent and synthetic steroid to treat various leukemias and other neoplasms. It causes gastrointestinal and bone marrow toxicity.
The transference of BONE MARROW from one human or animal to another for a variety of purposes including HEMATOPOIETIC STEM CELL TRANSPLANTATION or MESENCHYMAL STEM CELL TRANSPLANTATION.
Tumors or cancer of the TESTIS. Germ cell tumors (GERMINOMA) of the testis constitute 95% of all testicular neoplasms.
Substances that destroy fungi by suppressing their ability to grow or reproduce. They differ from FUNGICIDES, INDUSTRIAL because they defend against fungi present in human or animal tissues.
An orally administered anthracycline antineoplastic. The compound has shown activity against BREAST NEOPLASMS; LYMPHOMA; and LEUKEMIA.
A complex of related glycopeptide antibiotics from Streptomyces verticillus consisting of bleomycin A2 and B2. It inhibits DNA metabolism and is used as an antineoplastic, especially for solid tumors.
The ability of viruses to resist or to become tolerant to several structurally and functionally distinct drugs simultaneously. This resistance phenotype may be attributed to multiple gene mutation.
A biologic alkylating agent that exerts its cytotoxic effects by forming DNA ADDUCTS and DNA interstrand crosslinks, thereby inhibiting rapidly proliferating cells. The hydrochloride is an antineoplastic agent used to treat HODGKIN DISEASE and LYMPHOMA.
Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN.
Transplantation between individuals of the same species. Usually refers to genetically disparate individuals in contradistinction to isogeneic transplantation for genetically identical individuals.
A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.
An antitumor alkaloid isolated from VINCA ROSEA. (Merck, 11th ed.)
A nucleoside antibiotic isolated from Streptomyces antibioticus. It has some antineoplastic properties and has broad spectrum activity against DNA viruses in cell cultures and significant antiviral activity against infections caused by a variety of viruses such as the herpes viruses, the VACCINIA VIRUS and varicella zoster virus.
The removal of a limb or other appendage or outgrowth of the body. (Dorland, 28th ed)
Complete or partial surgical removal of the prostate. Three primary approaches are commonly employed: suprapubic - removal through an incision above the pubis and through the urinary bladder; retropubic - as for suprapubic but without entering the urinary bladder; and transurethral (TRANSURETHRAL RESECTION OF PROSTATE).
Cyclic hexapeptides of proline-ornithine-threonine-proline-threonine-serine. The cyclization with a single non-peptide bond can lead them to be incorrectly called DEPSIPEPTIDES, but the echinocandins lack ester links. Antifungal activity is via inhibition of 1,3-beta-glucan synthase production of BETA-GLUCANS.
Substances that inhibit or prevent the proliferation of NEOPLASMS.
Elements of limited time intervals, contributing to particular results or situations.
A glycoprotein that is a kallikrein-like serine proteinase and an esterase, produced by epithelial cells of both normal and malignant prostate tissue. It is an important marker for the diagnosis of prostate cancer.
Inhibitors of HIV PROTEASE, an enzyme required for production of proteins needed for viral assembly.
The application of probability and statistical methods to calculate the risk of occurrence of any event, such as onset of illness, recurrent disease, hospitalization, disability, or death. It may include calculation of the anticipated money costs of such events and of the premiums necessary to provide for payment of such costs.
Resistance or diminished response of a neoplasm to an antineoplastic agent in humans, animals, or cell or tissue cultures.
Therapy with two or more separate preparations given for a combined effect.
An anthracenedione-derived antineoplastic agent.
Malignant lymphoma composed of large B lymphoid cells whose nuclear size can exceed normal macrophage nuclei, or more than twice the size of a normal lymphocyte. The pattern is predominantly diffuse. Most of these lymphomas represent the malignant counterpart of B-lymphocytes at midstage in the process of differentiation.
Agents used to treat AIDS and/or stop the spread of the HIV infection. These do not include drugs used to treat symptoms or opportunistic infections associated with AIDS.
Methods which attempt to express in replicable terms the extent of the neoplasm in the patient.
The worsening of a disease over time. This concept is most often used for chronic and incurable diseases where the stage of the disease is an important determinant of therapy and prognosis.
Preparative treatment of transplant recipient with various conditioning regimens including radiation, immune sera, chemotherapy, and/or immunosuppressive agents, prior to transplantation. Transplantation conditioning is very common before bone marrow transplantation.
Neoplasms composed of primordial GERM CELLS of embryonic GONADS or of elements of the germ layers of the EMBRYO, MAMMALIAN. The concept does not refer to neoplasms located in the gonads or present in an embryo or FETUS.
A hypoperfusion of the BLOOD through an organ or tissue caused by a PATHOLOGIC CONSTRICTION or obstruction of its BLOOD VESSELS, or an absence of BLOOD CIRCULATION.
Inorganic or organic compounds that contain the basic structure RB(OH)2.
A neoplasm characterized by abnormalities of the lymphoid cell precursors leading to excessive lymphoblasts in the marrow and other organs. It is the most common cancer in children and accounts for the vast majority of all childhood leukemias.
A collective term for interstitial, intracavity, and surface radiotherapy. It uses small sealed or partly-sealed sources that may be placed on or near the body surface or within a natural body cavity or implanted directly into the tissues.
A class of drugs that differs from other alkylating agents used clinically in that they are monofunctional and thus unable to cross-link cellular macromolecules. Among their common properties are a requirement for metabolic activation to intermediates with antitumor efficacy and the presence in their chemical structures of N-methyl groups, that after metabolism, can covalently modify cellular DNA. The precise mechanisms by which each of these drugs acts to kill tumor cells are not completely understood. (From AMA, Drug Evaluations Annual, 1994, p2026)
Malignant lymphoma in which the lymphomatous cells are clustered into identifiable nodules within the LYMPH NODES. The nodules resemble to some extent the GERMINAL CENTER of lymph node follicles and most likely represent neoplastic proliferation of lymph node-derived follicular center B-LYMPHOCYTES.
An antineoplastic antimetabolite with immunosuppressant properties. It is an inhibitor of TETRAHYDROFOLATE DEHYDROGENASE and prevents the formation of tetrahydrofolate, necessary for synthesis of thymidylate, an essential component of DNA.
An HIV protease inhibitor that works by interfering with the reproductive cycle of HIV. It also inhibits CYTOCHROME P-450 CYP3A.
Carbon-containing phosphonic acid compounds. Included under this heading are compounds that have carbon bound to either OXYGEN atom or the PHOSPHOROUS atom of the (P=O)O2 structure.
Tumors or cancer of the PROSTATE.
Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals.
The degree to which BLOOD VESSELS are not blocked or obstructed.
Compounds which inhibit or antagonize the biosynthesis or actions of androgens.
The long-term (minutes to hours) administration of a fluid into the vein through venipuncture, either by letting the fluid flow by gravity or by pumping it.
Transplantation of stem cells collected from the peripheral blood. It is a less invasive alternative to direct marrow harvesting of hematopoietic stem cells. Enrichment of stem cells in peripheral blood can be achieved by inducing mobilization of stem cells from the BONE MARROW.
A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
Antibodies produced by a single clone of cells.
Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS).
The inferior part of the lower extremity between the KNEE and the ANKLE.
The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte.
Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group.
The anterior and posterior arteries created at the bifurcation of the popliteal artery. The anterior tibial artery begins at the lower border of the popliteus muscle and lies along the tibia at the distal part of the leg to surface superficially anterior to the ankle joint. Its branches are distributed throughout the leg, ankle, and foot. The posterior tibial artery begins at the lower border of the popliteus muscle, lies behind the tibia in the lower part of its course, and is found situated between the medial malleolus and the medial process of the calcaneal tuberosity. Its branches are distributed throughout the leg and foot.
A form of non-Hodgkin lymphoma having a usually diffuse pattern with both small and medium lymphocytes and small cleaved cells. It accounts for about 5% of adult non-Hodgkin lymphomas in the United States and Europe. The majority of mantle-cell lymphomas are associated with a t(11;14) translocation resulting in overexpression of the CYCLIN D1 gene (GENES, BCL-1).
An antineoplastic agent. It has significant activity against melanomas. (from Martindale, The Extra Pharmacopoeia, 31st ed, p564)
A nonparametric method of compiling LIFE TABLES or survival tables. It combines calculated probabilities of survival and estimates to allow for observations occurring beyond a measurement threshold, which are assumed to occur randomly. Time intervals are defined as ending each time an event occurs and are therefore unequal. (From Last, A Dictionary of Epidemiology, 1995)
Radiotherapy given to augment some other form of treatment such as surgery or chemotherapy. Adjuvant radiotherapy is commonly used in the therapy of cancer and can be administered before or after the primary treatment.
Antibodies from non-human species whose protein sequences have been modified to make them nearly identical with human antibodies. If the constant region and part of the variable region are replaced, they are called humanized. If only the constant region is modified they are called chimeric. INN names for humanized antibodies end in -zumab.
An organoplatinum compound that possesses antineoplastic activity.
The quantity of measurable virus in a body fluid. Change in viral load, measured in plasma, is sometimes used as a SURROGATE MARKER in disease progression.
A decrease in the number of NEUTROPHILS found in the blood.
Agents obtained from higher plants that have demonstrable cytostatic or antineoplastic activity.
Invasion of the host organism by microorganisms that can cause pathological conditions or diseases.
A family of 6-membered heterocyclic compounds occurring in nature in a wide variety of forms. They include several nucleic acid constituents (CYTOSINE; THYMINE; and URACIL) and form the basic structure of the barbiturates.
A cyclodecane isolated from the bark of the Pacific yew tree, TAXUS BREVIFOLIA. It stabilizes MICROTUBULES in their polymerized form leading to cell death.
Reinfusion of blood or blood products derived from the patient's own circulation. (Dorland, 27th ed)
Studies to determine the advantages or disadvantages, practicability, or capability of accomplishing a projected plan, study, or project.
The number of CD4-POSITIVE T-LYMPHOCYTES per unit volume of BLOOD. Determination requires the use of a fluorescence-activated flow cytometer.
An alkaloid isolated from the stem wood of the Chinese tree, Camptotheca acuminata. This compound selectively inhibits the nuclear enzyme DNA TOPOISOMERASES, TYPE I. Several semisynthetic analogs of camptothecin have demonstrated antitumor activity.
Antimetabolites that are useful in cancer chemotherapy.
Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries.
Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES.
The total amount of radiation absorbed by tissues as a result of radiotherapy.
Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.
A reverse transcriptase inhibitor and ZALCITABINE analog in which a sulfur atom replaces the 3' carbon of the pentose ring. It is used to treat HIV disease.
Inhibitors of reverse transcriptase (RNA-DIRECTED DNA POLYMERASE), an enzyme that synthesizes DNA on an RNA template.
A repeat operation for the same condition in the same patient due to disease progression or recurrence, or as followup to failed previous surgery.
The region of the lower limb in animals, extending from the gluteal region to the FOOT, and including the BUTTOCKS; HIP; and LEG.
Macrolide antifungal antibiotic produced by Streptomyces nodosus obtained from soil of the Orinoco river region of Venezuela.

Second-line treatment for primary central nervous system lymphoma. (1/1778)

Failure after first-line treatment was reported in 35-60% of immunocompetent patients with primary central nervous system lymphoma (PCNSL). There are currently no reports focusing on salvage therapy. This review analyses prognostic factors and the efficacy of salvage therapy by focusing on data from papers reporting results of first-line treatment in 355 cases. The study group consisted of 173 patients presenting treatment failure. The interval between failure and death (TTD) was compared for age at relapse (< or =60 vs. >60 years), type of failure (relapse vs. progression), time to relapse (< or =12 vs. >12 months) and salvage treatment (yes vs no). Median TTD was similar in younger and older patients (P = 0.09). Relapsed patients had a longer TTD than patients with progressive disease (P = 0.002). Early relapse led to a shorter TTD than late relapse (P = 0.005). Median TTD was 14 months for patients who underwent salvage therapy and 2 months for untreated cases (P<0.00001). A multivariate analysis showed an independent prognostic role for salvage therapy and time to relapse. Age and type of failure had no predictive value. Salvage therapy significantly improves outcome and, possibly, quality of life. As many different treatments were used conclusions cannot be made regarding an optimal treatment schedule.  (+info)

ESHAP as salvage therapy for refractory non-Hodgkin's lymphoma: Taiwan experience. (2/1778)

BACKGROUND: The ESHAP regimen, a combination of the chemotherapeutic drugs etoposide, methylprednisolone (solumedrol), high-dose cytarabine (ara-C) and cisplatin, has been shown to be active against refractory non-Hodgkin's lymphoma in therapeutic trials. We were interested in determining whether this regimen would be effective and tolerable for Chinese patients. METHODS: Thirty-two patients with refractory/relapsed non-Hodgkins lymphoma (23 intermediate-grade and nine high-grade) were enrolled in this study. Etoposide was administered at a dose of 40 mg/m2/day as a 1 h intravenous infusion from day 1 to day 4, solumedrol 500 mg/day was given as a 15 min intravenous infusion from day 1 to day 5, ara-C 2 g/m2 was given as a 2 h intravenous infusion on day 5 and cisplatin was given at a dose of 25 mg/m2/day as a continuous infusion from day 1 to day 4. Clinical efficacy and toxicity were assessed on the basis of the WHO criteria. RESULTS: Ten patients (31.3%, 95% Cl 15.2-47.4%) attained complete remission (CR) and seven had partial remission (PR). The overall response rate was 53.1% (95% Cl 35.8-70.4%). In eight of the 10 CR patients, the remission lasted for more than 8 months. The remaining two patients had CR of 5 and 6 months. The median duration of CR was 12.2 months (range 5-22 months). Myelosuppression with subsequent infections was the major toxicity. Severe leukopenia (WBC < 1000/microliter) lasted for an average of 12 days and thrombocytopenia (< 25,000/microliter) 18 days. One patient (3.1%) died of neutropenia-associated sepsis within 4 weeks after treatment. Non-myeloid toxicities included alopecia in 66% (28% grade 2, 22% grade 3), stomatitis in 72% (25% grade 2, 28% grade 3, 13% grade 4), hepatotoxicity in 9% (3% grade 2), renal toxicity in 13% (6% grade 2, 3% grade 3) and infection in 56% (18% grade 2, 25% grade 3, 13% grade 4). The majority of the responders relapsed within 2 years after ESHAP treatment. Median survival for all patients was 8.6 months. CONCLUSIONS: ESHAP is an active and tolerable regimen in Chinese patients with relapsed/refractory lymphoma, but the duration of remission is brief and without significant impact on survival.  (+info)

Early harvest and late transplantation as an effective therapeutic strategy in multiple myeloma. (3/1778)

Transplantation after high-dose chemotherapy prolongs survival in patients with multiple myeloma compared with standard therapy. It is unclear whether the optimal timing of transplantation is immediately after induction chemotherapy or whether stem cells may be cryopreserved for transplantation at subsequent progression or relapse. In this study, stem cells were collected within 6 months of diagnosis, followed by transplantation only at progression of myeloma. One hundred and eighteen patients with multiple myeloma had stem cells collected and cryopreserved. Eleven had transplants early in the disease after they demonstrated failure to respond to primary therapy. The remaining 107 were eligible for transplants when there was evidence of progressive disease. Of the 118 patients, 67 had transplants, nine died of progressive disease before transplantation, and 42 remain alive in plateau phase. The median survival of the group is 58.5 months; 67 are alive. Serum beta2-microglobulin, bone marrow labeling index (S phase), and hemoglobin level predicted overall survival (P < 0.006, P < 0.001, and P < 0.01, respectively). We conclude that early cryopreservation of blood stem cells followed by transplantation at progression is a feasible approach to therapy in patients with myeloma. The underlying biology of the disease has a greater impact on survival than the timing of transplantation. A prospective randomized trial is required to answer definitively the question of the optimal timing of blood cell transplantation.  (+info)

High-dose therapy with autologous or allogeneic transplantation as salvage therapy for small cleaved cell lymphoma of follicular center cell origin. (4/1778)

Between 1985 and 1996, 51 patients with relapsed or refractory small cleaved cell lymphoma (SCCL) received high-dose chemotherapy +/- TBI in conjunction with autologous (ABMT) (36 patients) or allogeneic transplantation (15 patients). Patients were eligible for ABMT if the bone marrow biopsy done prior to the planned transplant did not reveal microscopic involvement with SCCL. Patients receiving ABMT had a median age of 48 years, had received a median of 2.5 chemotherapy regimens prior to transplantation, and were transplanted a median of 35.5 months from diagnosis. Among patients receiving ABMT, 5 year actuarial survival was 56+/-11%. Median survival was 126+ months, and median survival from diagnosis was 191 months. Univariate and multivariate analysis identified sensitive disease as the best predictor of a favorable response. Five-year actuarial survival was 66+/-12% for patients with sensitive disease at the time of transplant as compared to 29+/-17% for patients with resistant disease, P = 0.015. Median survival in patients with sensitive disease at the time of ABMT was 126+ months. By univariate analysis, survival was significantly better for patients receiving ABMT as compared to patients receiving allogeneic transplants. Median survival following allogeneic transplantation was 5 months; 5 year actuarial survival was 15+/-13%. In a multivariate analysis, which considered autologous vs allogeneic transplantation, sensitive vs resistant disease, <3 vs > or = 3 prior treatments, and prior bone marrow involvement, allogeneic transplantation was significantly associated with poor survival. Treatment-related mortality occurred in eight of 15 patients receiving allogeneic transplantation and limited the effectiveness of this therapy. High-dose therapy in conjunction with ABMT is effective therapy for patients with SCCL whose disease is sensitive to chemotherapy and whose marrows are microscopically free of disease. Because of possible selection bias, it has not been proven that this approach increases survival in these patients. Treatment-related mortality limits the effectiveness of allogeneic transplantation in SCCL.  (+info)

Autologous transplantation of chemotherapy-purged PBSC collections from high-risk leukemia patients: a pilot study. (5/1778)

We have recently demonstrated that the combination of the alkylating agent nitrogen mustard (NM) and etoposide (VP-16) is capable of eliminating, ex vivo, leukemic cells contaminating PBSC collections and this is associated with a significant recovery of primitive and committed hematopoietic progenitor cells. Based on these data a pilot study on autologous transplantation of NM/VP-16 purged PBSC for high-risk leukemic patients was recently initiated. Twelve patients (seven females and five males) with a median age of 46 years (range 18-57) have been treated. Two patients had acute myeloblastic leukemia (AML) resistant to conventional induction treatment, four patients had secondary AML in I complete remission (CR), one patient was in II CR after failing a previous autologous BM transplantation, while two additional AML individuals were in I CR achieved after three or more cycles of induction treatment. Two patients with high-risk acute lymphoblastic leukemia (ALL) in I CR and one patient with mantle cell lymphoma and leukemic dissemination were also included. Eight patients showed karyotypic abnormalities associated with a poor clinical outcome. The mobilizing regimens included cytosine arabinoside and mitoxantrone with (n = 6) or without fludarabine (n = 3) followed by subcutaneous administration of G-CSF (5 microg/kg/day until the completion of PBSC collection) and G-CSF alone (n = 3) (15 microg/kg/day). A median of two aphereses (range 1-3) allowed the collection of 7.2 x 10(8) TNC/kg (range 3.4-11.5), 5 x 10(6) CD34+ cells/kg (range 2.1-15.3) and 9.2 x 10(4) CFU-GM/kg (0.3-236). PBSC were treated with a constant dose of 20 microg of VP-16/ml and a median individual-adjusted dose (survival < or = 5% of steady-state BM CFU-GM) of NM of 0.7 microg/ml (range 0.25-1.25). Eleven patients were reinfused after busulfan (16 mg/kg) and Cy (120 mg/kg) conditioning with a median residual dose of 0.3 x 10(4) CFU-GM/kg (0-11.5). The median time to neutrophil engraftment (>0.5 x 10(9)/l) for evaluable patients was 25 days (range 12-59); the median time to platelet transfusion independence (>20 and >50 x 10(9)/l) was 40 days (18-95) and 69 days (29-235), respectively. Hospital discharge occurred at a median of 25 days (18-58) after stem cell reinfusion. Four individuals are alive in CR (n = 3) or with residual nodal disease (n = 1 lymphoma patient) with a follow-up of 32, 26, 3 and 14 months, respectively. Seven patients died due to disease progression or relapse (n = 5) or extrahematological transplant toxicity (n = 2). Our data suggest that pharmacological purging of leukapheresis collections of leukemic patients at high-risk of relapse is feasible and ex vivo treated cells reconstitute autologous hematopoiesis.  (+info)

Feasibility of immunotherapy of relapsed leukemia with ex vivo-generated cytotoxic T lymphocytes specific for hematopoietic system-restricted minor histocompatibility antigens. (6/1778)

Allogeneic bone marrow transplantation (BMT) is a common treatment of hematologic malignancies. Recurrence of the underlying malignancy is a major cause of treatment failure. Donor-derived cytotoxic T lymphocytes (CTLs) specific for patients' minor histocompatibility antigens (mHags) play an important role in both graft-versus-host disease (GVHD) and graft-versus-leukemia (GVL) reactivities. mHags HA-1 and HA-2 induce HLA-A*0201-restricted CTLs in vivo and are exclusively expressed on hematopoietic cells, including leukemic cells and leukemic precursors, but not on fibroblasts, keratinocytes, or liver cells. The chemical nature of the mHags HA-1 and HA-2 is known. We investigated the feasibility of ex vivo generation of mHag HA-1- and HA-2-specific CTLs from unprimed mHag HA-1- and/or HA-2-negative healthy blood donors. HA-1 and HA-2 synthetic peptide-pulsed dendritic cells (DCs) were used as antigen-presenting cells (APC) to stimulate autologous unprimed CD8(+) T cells. The ex vivo-generated HA-1- and HA-2-specific CTLs efficiently lyse leukemic cells derived from acute myeloid leukemia (AML) and acute lymphoid leukemia (ALL) patients. No lytic reactivity was detected against nonhematopoietic cells. Sufficient numbers of the CTLs can be obtained for the adoptive immunotherapy purposes. In conclusion, we present a feasible, novel therapy for the treatment for relapsed leukemia after BMT with a low risk of GVHD.  (+info)

Treatment of multiple myeloma. (7/1778)

BACKGROUND AND OBJECTIVE: Multiple myeloma (MM) accounts for about 10% of all hematologic malignancies. The standard treatment with intermittent courses of melphalan and prednisone (MP) was introduced more than 30 years ago and, since then there has been little improvement in event-free and overall survival (EFS & OS). The aim of this article is to review: 1) the role of initial chemotherapy (ChT), maintenance treatment with alpha-interferon and salvage ChT, 2) the results of high-dose therapy (HDT) followed by allogeneic or autologous stem cell transplantation (allo-SCT and auto-SCT), and 3) the most important supportive measures. EVIDENCE AND INFORMATION SOURCES: The authors of this review have been actively working and contributing with original investigations on the treatment of MM during the last 15 years. In addition, the most relevant articles and recent abstracts published in journals covered by the Science Citation Index and Medline are also reviewed. STATE OF THE ART AND PERSPECTIVES: The importance of avoiding ChT in asymptomatic patients (smoldering MM) is emphasized. The criteria and patterns of response are reviewed. MP is still the standard initial ChT with a response rate of 50-60% and an OS of 2-3 years. Combination ChT usually increases the response rate but does not significantly influence survival when compared with MP. Exposure to melphalan should be avoided in patients in whom HDT followed by auto-SCT is planned, in order to not preclude the stem cell collection. The median response duration to initial ChT is 18 months. Interferon maintenance usually prolongs response duration but in most studies does not significantly influence survival (a large meta-analysis by the Myeloma Trialists' Collaborative Group in Oxford is being finished). In alkylating-resistant patients, the best rescue regimens are VBAD or VAD. In patients already resistant to VBAD or VAD and in those in whom these treatments are not feasible we recommend a conservative approach with alternate day prednisone and pulse cyclophosphamide. While HDT followed by autotransplantation is not recommended for patients with resistant relapse, patients with primary refractory disease seem to benefit from early myeloablative therapy. Although results from large randomized trials are still pending in order to establish whether early HDT intensification followed by auto-SCT is superior to continuing standard ChT in responding patients, the favorable experience with autotransplantation of the French Myeloma Intergroup supports this approach. However, although the complete response rate is higher with intensive therapy, the median duration of response is relatively short (median, 16 to 36 months), with no survival plateau. There are several ongoing trials comparing conventional ChT with HDT/autoSCT in order to identify the patients who are likely to benefit from one or another approach. With allo-SCT there is a transplant-related mortality ranging from 30 to 50% and also a high relapse rate in patients achieving CR. However, 10 to 20% of patients undergoing allo-SCT are long-term survivors (> 5 years) with no evidence of disease and, consequently, probably cured. The use of allogeneic peripheral blood stem cells (PBSC) in order to speed the engraftment and also the use of partially T-cell depleted PBSC which can decrease the incidence of graft-versus-host disease are promising approaches. In the setting of allo-SCT, donor lymphocyte infusion is an encouraging strategy in order to treat or prevent relapses. Finally, important supportive measures such as the treatment of anemia with erythropoietin, the management of renal failure and the use of bisphosphonates are reviewed.  (+info)

Costs of high-dose salvage therapy and blood stem cell transplantation for resistant-relapsed malignant lymphomas in a southern Italian hospital. (8/1778)

BACKGROUND AND OBJECTIVE: Analysis of costs of high technological procedures such as peripheral blood stem cell (PBSC) autotransplantation in lymphomas are generally finalized at disclosing whether the improvement of survival in a subset of patients is cost effective and whether the cost of the procedure could be reduced. With the aim of revealing a possibility of reducing costs with respect to conditions of safety, we present our experience with PBSC autotransplantation in a particularly poor prognosis subset of patients with lymphoma. DESIGN AND METHODS: The expenses are analyzed for groups of cost and main resources necessary at unitary cost are considered separately. Groups of cost include various phases of the PBSC autotransplantation such as preparative procedures, execution of myeloablative therapy, reinfusion of CD34 cells, supportive therapy after reinfusion until discharge of the patient, general support for the management of patient. All costs are calculated according to 1997 prices and salaries and reported in dollars. The analysis was conducted on 21 patients with lymphoma resistant to other therapies treated by myeloablative therapy and PBSC autotransplantation in an hematologic unit in an open ward; the assistance was provided by staff not exclusively dedicated to bone marrow transplant procedures, with some help from a family member. RESULTS: The PBSC procedure, including all phases, costs from $17,761.9 to $18,259.9 depending on the type of myeloablative therapy employed; the mean cost was $18,092.6. The preparative phase with mobilization of CD34 cells, cryopreservation and reinfusion costed $3,538.7 (19.6% of the total cost); a major cost of this phase was cryopreservation and CD34 manipulation ($857.1). The second phase with myeloablative therapy and reinfusion of CD34 cells had a mean cost of $2,785.9 (15.4% of the total cost); a major cost of this phase was the hospitalization ($1,119.8). The third phase of patient's support after treatment had a total cost of $7,649 (42.3% of the cost of the total procedure) with the major cost being due to hospitalization ($2,571) calculated on a mean of 15 days after the reinfusion of CD-34. The last group of costs, including management support, accounted for $4,119 (22.7%) with a major cost being amortization of the structure ($1,600). The general cost for nurse's assistance to the patient was $1,355.1 (7.5%). INTERPRETATION AND CONCLUSIONS: A procedure of PBSC autotransplantation in resistant lymphoma is affordable without the strict precautions generally given in intensive care units. This provides a substantial reduction of expenses because of the low number of specifically trained staff members and the generally low cost of the necessary supplies. Before, however, proposing PBSC autotransplantation in most patients with resistant lymphoma, an evaluation of whether costs could be further reduced and whether the procedure has a cost benefit impact is needed.  (+info)

Hodgkin Disease can spread to other parts of the body through the lymphatic system, and it can affect people of all ages, although it is most common in young adults and teenagers. The symptoms of Hodgkin Disease can vary depending on the stage of the disease, but they may include swollen lymph nodes, fever, night sweats, fatigue, weight loss, and itching.

There are several types of Hodgkin Disease, including:

* Classical Hodgkin Disease: This is the most common type of Hodgkin Disease and is characterized by the presence of Reed-Sternberg cells.
* Nodular Lymphocytic predominant Hodgkin Disease: This type of Hodgkin Disease is characterized by the presence of nodules in the lymph nodes.
* Mixed Cellularity Hodgkin Disease: This type of Hodgkin Disease is characterized by a mixture of Reed-Sternberg cells and other immune cells.

Hodgkin Disease is usually diagnosed with a biopsy, which involves removing a sample of tissue from the affected lymph node or other area and examining it under a microscope for cancer cells. Treatment for Hodgkin Disease typically involves chemotherapy, radiation therapy, or a combination of both. In some cases, bone marrow or stem cell transplantation may be necessary.

The prognosis for Hodgkin Disease is generally good, especially if the disease is detected and treated early. According to the American Cancer Society, the 5-year survival rate for people with Hodgkin Disease is about 85%. However, the disease can sometimes recur after treatment, and the long-term effects of radiation therapy and chemotherapy can include infertility, heart problems, and an increased risk of secondary cancers.

Hodgkin Disease is a rare form of cancer that affects the immune system. It is most commonly diagnosed in young adults and is usually treatable with chemotherapy or radiation therapy. However, the disease can sometimes recur after treatment, and the long-term effects of treatment can include infertility, heart problems, and an increased risk of secondary cancers.

Recurrence can also refer to the re-emergence of symptoms in a previously treated condition, such as a chronic pain condition that returns after a period of remission.

In medical research, recurrence is often studied to understand the underlying causes of disease progression and to develop new treatments and interventions to prevent or delay its return.

This definition of 'Neoplasm Recurrence, Local' is from the Healthcare Professionals edition of the Merriam-Webster Medical Dictionary, copyright © 2007 by Merriam-Webster, Inc.

Germinomas are rare and account for only about 1% to 3% of all germ cell tumors. They are more common in children and young adults, and the median age at diagnosis is around 10 to 20 years. These tumors tend to grow slowly and may not cause any symptoms in their early stages.

The signs and symptoms of germinoma can vary depending on the location and size of the tumor. In general, they may include:

* Abdominal pain or discomfort
* Swelling or lump in the abdomen
* Vaginal bleeding or discharge in females
* Painful urination or scrotal swelling in males
* Fatigue or fever

If a germinoma is suspected, imaging tests such as CT scans, MRI scans, or ultrasound may be ordered to confirm the diagnosis. A biopsy may also be performed to examine the tumor cells under a microscope.

Treatment for germinoma typically involves surgery to remove the tumor and any affected tissues. In some cases, chemotherapy or radiation therapy may be recommended to ensure that all cancerous cells are eliminated. The prognosis for germinoma is generally good, with a five-year survival rate of around 90% for children and young adults. However, the tumor can recur in some cases, so follow-up care is important.

In summary, germinoma is a rare type of tumor that originates from germ cells in the reproductive system. It can be benign or malignant and tends to grow slowly, causing abdominal pain, swelling, or other symptoms. Treatment typically involves surgery and may include chemotherapy or radiation therapy, with a good prognosis for most patients.

There are several subtypes of NHL, including:

1. B-cell lymphomas (such as diffuse large B-cell lymphoma and follicular lymphoma)
2. T-cell lymphomas (such as peripheral T-cell lymphoma and mycosis fungoides)
3. Natural killer cell lymphomas (such as nasal NK/T-cell lymphoma)
4. Histiocyte-rich B-cell lymphoma
5. Primary mediastinal B-cell lymphoma
6. Mantle cell lymphoma
7. Waldenström macroglobulinemia
8. Lymphoplasmacytoid lymphoma
9. Myelodysplastic syndrome/myeloproliferative neoplasms (MDS/MPN) related lymphoma

These subtypes can be further divided into other categories based on the specific characteristics of the cancer cells.

Symptoms of NHL can vary depending on the location and size of the tumor, but may include:

* Swollen lymph nodes in the neck, underarm, or groin
* Fever
* Fatigue
* Weight loss
* Night sweats
* Itching
* Abdominal pain
* Swollen spleen

Treatment for NHL typically involves a combination of chemotherapy, radiation therapy, and in some cases, targeted therapy or immunotherapy. The specific treatment plan will depend on the subtype of NHL, the stage of the cancer, and other individual factors.

Overall, NHL is a complex and diverse group of cancers that require specialized care from a team of medical professionals, including hematologists, oncologists, radiation therapists, and other support staff. With advances in technology and treatment options, many people with NHL can achieve long-term remission or a cure.

The term anticipatory vomiting is used to describe the phenomenon where an individual experiences nausea and vomiting before undergoing a medical procedure, taking medication, or experiencing certain types of stimuli. The exact cause of anticipatory vomiting is not fully understood, but it is thought to be related to the activation of the brain's fear and anxiety centers.

Anticipatory vomiting can be caused by a variety of factors, including:

1. Previous negative experiences: Individuals who have experienced negative events or procedures in the past may anticipate similar experiences in the future and exhibit symptoms of anticipatory vomiting.
2. Fear and anxiety: The anticipation of a potentially unpleasant experience can cause individuals to feel anxious and fearful, which can lead to nausea and vomiting.
3. Conditioning: Classical conditioning, a psychological phenomenon where an individual learns to associate certain stimuli with negative outcomes, can contribute to the development of anticipatory vomiting.
4. Medical conditions: Certain medical conditions, such as migraines or motion sickness, can trigger anticipatory vomiting.
5. Medications: Some medications can cause nausea and vomiting as a side effect, which can lead to anticipatory vomiting in individuals who anticipate taking these medications.

The diagnosis of anticipatory vomiting typically involves a comprehensive medical history and physical examination to rule out other potential causes of the symptoms. Treatment for anticipatory vomiting may include:

1. Anti-anxiety medication: Medications such as benzodiazepines or selective serotonin reuptake inhibitors (SSRIs) can help reduce anxiety and alleviate symptoms of anticipatory vomiting.
2. Cognitive behavioral therapy (CBT): CBT can help individuals identify and change negative thought patterns and behaviors that contribute to anticipatory vomiting.
3. Relaxation techniques: Techniques such as deep breathing, progressive muscle relaxation, and mindfulness meditation can help individuals manage anxiety and reduce the likelihood of anticipatory vomiting.
4. Desensitization therapy: This type of therapy involves gradually exposing individuals to the feared situation or stimulus in a controlled and safe environment to help them become desensitized to their fears.
5. Avoiding triggers: Identifying and avoiding triggers for anticipatory vomiting, such as certain situations or medications, can help manage symptoms.

In summary, anticipatory vomiting is a condition where individuals experience nausea and vomiting in anticipation of a potentially unpleasant experience. It can be caused by a variety of factors, including psychological and medical conditions, and treated with a combination of medications, therapy, and lifestyle changes.

The symptoms of aspergillosis depend on the location and severity of the infection. In the lungs, it may cause coughing, fever, chest pain, and difficulty breathing. In the sinuses, it can cause headaches, facial pain, and nasal congestion. In the brain, it can cause seizures, confusion, and weakness.

Aspergillosis is typically diagnosed through a combination of imaging tests such as chest X-rays, CT scans, and MRI scans, along with a biopsy to confirm the presence of Aspergillus fungi.

Treatment of aspergillosis depends on the severity and location of the infection. In mild cases, treatment may involve antifungal medications and supportive care such as oxygen therapy and pain management. In severe cases, treatment may require hospitalization and intravenous antifungal medications.

Preventive measures for aspergillosis include avoiding exposure to dusty or damp environments, managing chronic conditions such as asthma and COPD, and taking antifungal medications as prescribed.

Aspergillosis can be a serious condition, especially in people with weakened immune systems, such as those with cancer, HIV/AIDS, or taking immunosuppressive drugs. In severe cases, aspergillosis can lead to life-threatening complications such as respiratory failure, sepsis, and organ damage.

In conclusion, aspergillosis is a common fungal infection that can affect various parts of the body, and it can be serious and potentially life-threatening, especially in people with weakened immune systems. Early diagnosis and appropriate treatment are essential to prevent complications and improve outcomes.

Multiple myeloma is the second most common type of hematologic cancer after non-Hodgkin's lymphoma, accounting for approximately 1% of all cancer deaths worldwide. It is more common in older adults, with most patients being diagnosed over the age of 65.

The exact cause of multiple myeloma is not known, but it is believed to be linked to genetic mutations that occur in the plasma cells. There are several risk factors that have been associated with an increased risk of developing multiple myeloma, including:

1. Family history: Having a family history of multiple myeloma or other plasma cell disorders increases the risk of developing the disease.
2. Age: The risk of developing multiple myeloma increases with age, with most patients being diagnosed over the age of 65.
3. Race: African Americans are at higher risk of developing multiple myeloma than other races.
4. Obesity: Being overweight or obese may increase the risk of developing multiple myeloma.
5. Exposure to certain chemicals: Exposure to certain chemicals such as pesticides, solvents, and heavy metals has been linked to an increased risk of developing multiple myeloma.

The symptoms of multiple myeloma can vary depending on the severity of the disease and the organs affected. Common symptoms include:

1. Bone pain: Pain in the bones, particularly in the spine, ribs, or long bones, is a common symptom of multiple myeloma.
2. Fatigue: Feeling tired or weak is another common symptom of the disease.
3. Infections: Patients with multiple myeloma may be more susceptible to infections due to the impaired functioning of their immune system.
4. Bone fractures: Weakened bones can lead to an increased risk of fractures, particularly in the spine, hips, or ribs.
5. Kidney problems: Multiple myeloma can cause damage to the kidneys, leading to problems such as kidney failure or proteinuria (excess protein in the urine).
6. Anemia: A low red blood cell count can cause anemia, which can lead to fatigue, weakness, and shortness of breath.
7. Increased calcium levels: High levels of calcium in the blood can cause symptoms such as nausea, vomiting, constipation, and confusion.
8. Neurological problems: Multiple myeloma can cause neurological problems such as headaches, numbness or tingling in the arms and legs, and difficulty with coordination and balance.

The diagnosis of multiple myeloma typically involves a combination of physical examination, medical history, and laboratory tests. These may include:

1. Complete blood count (CBC): A CBC can help identify abnormalities in the numbers and characteristics of different types of blood cells, including red blood cells, white blood cells, and platelets.
2. Serum protein electrophoresis (SPEP): This test measures the levels of different proteins in the blood, including immunoglobulins (antibodies) and abnormal proteins produced by myeloma cells.
3. Urine protein electrophoresis (UPEP): This test measures the levels of different proteins in the urine.
4. Immunofixation: This test is used to identify the type of antibody produced by myeloma cells and to rule out other conditions that may cause similar symptoms.
5. Bone marrow biopsy: A bone marrow biopsy involves removing a sample of tissue from the bone marrow for examination under a microscope. This can help confirm the diagnosis of multiple myeloma and determine the extent of the disease.
6. Imaging tests: Imaging tests such as X-rays, CT scans, or MRI scans may be used to assess the extent of bone damage or other complications of multiple myeloma.
7. Genetic testing: Genetic testing may be used to identify specific genetic abnormalities that are associated with multiple myeloma and to monitor the response of the disease to treatment.

It's important to note that not all patients with MGUS or smoldering myeloma will develop multiple myeloma, and some patients with multiple myeloma may not have any symptoms at all. However, if you are experiencing any of the symptoms listed above or have a family history of multiple myeloma, it's important to talk to your doctor about your risk and any tests that may be appropriate for you.

1. Zygomycosis is a rare and opportunistic fungal infection caused by members of the order Ophiostomatales, which primarily affects the skin and subcutaneous tissues, but can also disseminate to other organs and cause severe systemic disease.
2. Zygomycosis is a type of deep mycosis that is characterized by the presence of broad, flat pseudohyphae and/or thick-walled spherules in the infected tissue, typically seen on histopathological examination.
3. Zygomycosis is an invasive fungal infection that can affect various parts of the body, including the skin, soft tissues, bones, and organs, and is often associated with underlying conditions such as diabetes, immunodeficiency, or malignancy.
4. Zygomycosis is a rare and aggressive fungal infection that can cause significant morbidity and mortality if left untreated, and early diagnosis and treatment are essential to prevent progression of the disease.

Testicular neoplasms refer to abnormal growths or tumors that develop in the testicles, which are located inside the scrotum. These tumors can be benign (non-cancerous) or malignant (cancerous). Testicular neoplasms can affect men of all ages, but they are more common in younger men between the ages of 20 and 35.

Types of Testicular Neoplasms:

There are several types of testicular neoplasms, including:

1. Seminoma: This is a type of malignant tumor that develops from immature cells in the testicles. It is the most common type of testicular cancer and tends to grow slowly.
2. Non-seminomatous germ cell tumors (NSGCT): These are malignant tumors that develop from immature cells in the testicles, but they do not have the characteristic features of seminoma. They can be either heterologous (containing different types of cells) or homologous (containing only one type of cell).
3. Leydig cell tumors: These are rare malignant tumors that develop in the Leydig cells, which produce testosterone in the testicles.
4. Sertoli cell tumors: These are rare malignant tumors that develop in the Sertoli cells, which support the development of sperm in the testicles.
5. Testicular metastasectomy: This is a procedure to remove cancer that has spread to the testicles from another part of the body, such as the lungs or liver.

Causes and Risk Factors:

The exact cause of testicular neoplasms is not known, but there are several risk factors that have been linked to an increased risk of developing these tumors. These include:

1. Undescended testicles (cryptorchidism): This condition occurs when the testicles do not descend into the scrotum during fetal development.
2. Family history: Men with a family history of testicular cancer are at an increased risk of developing these tumors.
3. Previous radiation exposure: Men who have had radiation therapy to the pelvic area, especially during childhood or adolescence, have an increased risk of developing testicular neoplasms.
4. Genetic mutations: Certain genetic mutations, such as those associated with familial testicular cancer syndrome, can increase the risk of developing testicular neoplasms.
5. Infertility: Men who are infertile may have an increased risk of developing testicular cancer.

Symptoms:

The symptoms of testicular neoplasms can vary depending on the type and location of the tumor. Some common symptoms include:

1. A lump or swelling in the testicle
2. Pain or discomfort in the testicle or scrotum
3. Enlargement of the testicle
4. Abnormality in the size or shape of the testicle
5. Pain during ejaculation
6. Difficulty urinating or painful urination
7. Breast tenderness or enlargement
8. Lower back pain
9. Fatigue
10. Weight loss

Diagnosis:

The diagnosis of testicular neoplasms typically involves a combination of physical examination, imaging studies, and biopsy.

1. Physical examination: A doctor will perform a thorough physical examination of the testicles, including checking for any abnormalities in size, shape, or tenderness.
2. Imaging studies: Imaging studies such as ultrasound, CT scans, or MRI may be used to help identify the location and extent of the tumor.
3. Biopsy: A biopsy is a procedure in which a small sample of tissue is removed from the testicle and examined under a microscope for cancer cells.
4. Blood tests: Blood tests may be performed to check for elevated levels of certain substances that can indicate the presence of cancer.

Treatment:

The treatment of testicular neoplasms depends on the type, location, and stage of the tumor. Some common treatments include:

1. Surgery: Surgery is often the first line of treatment for testicular neoplasms. The goal of surgery is to remove the tumor and any affected tissue.
2. Chemotherapy: Chemotherapy may be used in combination with surgery or radiation therapy to treat more advanced cancers.
3. Radiation therapy: Radiation therapy uses high-energy beams to kill cancer cells. It may be used in combination with surgery or chemotherapy.
4. Surveillance: Surveillance is a close monitoring of the patient's condition, including regular check-ups and imaging studies, to detect any recurrences of the tumor.

Prognosis:

The prognosis for testicular neoplasms depends on the type, location, and stage of the tumor. In general, the earlier the cancer is detected and treated, the better the prognosis. Some common types of testicular neoplasms have a good prognosis, while others are more aggressive and may have a poorer prognosis if not treated promptly.

Complications:

Some complications of testicular neoplasms include:

1. Recurrence: The cancer can recur in the testicle or spread to other parts of the body.
2. Spread to other parts of the body: Testicular cancer can spread to other parts of the body, such as the lungs, liver, or brain.
3. Infertility: Some treatments for testicular cancer, such as chemotherapy and radiation therapy, can cause infertility.
4. Hormone imbalance: Some types of testicular cancer can disrupt hormone levels, leading to symptoms such as breast enlargement or low sex drive.
5. Chronic pain: Some men may experience chronic pain in the testicle or scrotum after treatment for testicular cancer.

Lifestyle changes:

There are no specific lifestyle changes that can prevent testicular neoplasms, but some general healthy habits can help reduce the risk of developing these types of tumors. These include:

1. Maintaining a healthy weight and diet
2. Getting regular exercise
3. Limiting alcohol consumption
4. Avoiding smoking and recreational drugs
5. Protecting the testicles from injury or trauma

Screening:

There is no standard screening test for testicular neoplasms, but men can perform a self-exam to check for any abnormalities in their testicles. This involves gently feeling the testicles for any lumps or unusual texture. Men with a family history of testicular cancer should talk to their doctor about whether they should start screening earlier and more frequently.

Treatment:

The treatment of testicular neoplasms depends on the type, stage, and location of the tumor. Some common treatments include:

1. Surgery: This involves removing the affected testicle or tumor.
2. Chemotherapy: This involves using drugs to kill cancer cells.
3. Radiation therapy: This involves using high-energy rays to kill cancer cells.
4. Hormone therapy: This involves taking medications to alter hormone levels and slow the growth of cancer cells.
5. Clinical trials: These involve testing new treatments or combination of treatments for testicular neoplasms.

Prognosis:

The prognosis for testicular neoplasms varies depending on the type, stage, and location of the tumor. In general, the earlier the cancer is detected and treated, the better the prognosis. For example, seminoma has a high cure rate with current treatments, while non-seminomatous germ cell tumors have a lower cure rate but can still be effectively treated. Lymphoma and metastatic testicular cancer have a poorer prognosis and require aggressive treatment.

Lifestyle Changes:

There are no specific lifestyle changes that can prevent testicular neoplasms, but some risk factors such as smoking and alcohol consumption can be reduced to lower the risk of developing these tumors. Maintaining a healthy diet, regular exercise, and avoiding exposure to harmful chemicals can also help improve overall health and well-being.

Complications:

Testicular neoplasms can have several complications, including:

1. Infertility: Some treatments for testicular cancer, such as surgery or chemotherapy, can cause infertility.
2. Pain: Testicular cancer can cause pain in the scrotum, groin, or abdomen.
3. Swelling: Testicular cancer can cause swelling in the scrotum or groin.
4. Hormonal imbalance: Some testicular tumors can produce hormones that can cause an imbalance in the body's hormone levels.
5. Recurrence: Testicular cancer can recur after treatment, and regular follow-up is necessary to detect any signs of recurrence early.
6. Late effects of treatment: Some treatments for testicular cancer, such as chemotherapy, can have long-term effects on the body, including infertility, heart problems, and bone marrow suppression.
7. Metastasis: Testicular cancer can spread to other parts of the body, including the lungs, liver, and bones, which can be life-threatening.

Prevention:

There is no specific prevention for testicular neoplasms, but some risk factors such as undescended testes, family history, and exposure to certain chemicals can be reduced to lower the risk of developing these tumors. Regular self-examination and early detection are crucial in improving outcomes for patients with testicular cancer.

Conclusion:

Testicular neoplasms are a rare but potentially life-threatening condition that requires prompt and accurate diagnosis and treatment. Early detection through regular self-examination and follow-up can improve outcomes, while awareness of risk factors and symptoms is essential in reducing the burden of this disease. A multidisciplinary approach involving urologists, radiologists, pathologists, and oncologists is necessary for optimal management of patients with testicular neoplasms.

DLBCL is characterized by the rapid growth of malignant B cells in the lymph nodes, spleen, bone marrow, and other organs. These cells can also spread to other parts of the body through the bloodstream or lymphatic system. The disease is often aggressive and can progress quickly without treatment.

The symptoms of DLBCL vary depending on the location and extent of the disease, but they may include:

* Swollen lymph nodes in the neck, underarm, or groin
* Fever
* Fatigue
* Night sweats
* Weight loss
* Abdominal pain or discomfort
* Itching

The diagnosis of DLBCL is based on a combination of physical examination findings, imaging studies (such as CT scans or PET scans), and biopsy results. Treatment typically involves a combination of chemotherapy, radiation therapy, and in some cases, immunotherapy or targeted therapy. The prognosis for DLBCL has improved significantly over the past few decades, with overall survival rates ranging from 60% to 80%, depending on the stage and other factors.

Disease progression can be classified into several types based on the pattern of worsening:

1. Chronic progressive disease: In this type, the disease worsens steadily over time, with a gradual increase in symptoms and decline in function. Examples include rheumatoid arthritis, osteoarthritis, and Parkinson's disease.
2. Acute progressive disease: This type of disease worsens rapidly over a short period, often followed by periods of stability. Examples include sepsis, acute myocardial infarction (heart attack), and stroke.
3. Cyclical disease: In this type, the disease follows a cycle of worsening and improvement, with periodic exacerbations and remissions. Examples include multiple sclerosis, lupus, and rheumatoid arthritis.
4. Recurrent disease: This type is characterized by episodes of worsening followed by periods of recovery. Examples include migraine headaches, asthma, and appendicitis.
5. Catastrophic disease: In this type, the disease progresses rapidly and unpredictably, with a poor prognosis. Examples include cancer, AIDS, and organ failure.

Disease progression can be influenced by various factors, including:

1. Genetics: Some diseases are inherited and may have a predetermined course of progression.
2. Lifestyle: Factors such as smoking, lack of exercise, and poor diet can contribute to disease progression.
3. Environmental factors: Exposure to toxins, allergens, and other environmental stressors can influence disease progression.
4. Medical treatment: The effectiveness of medical treatment can impact disease progression, either by slowing or halting the disease process or by causing unintended side effects.
5. Co-morbidities: The presence of multiple diseases or conditions can interact and affect each other's progression.

Understanding the type and factors influencing disease progression is essential for developing effective treatment plans and improving patient outcomes.

Examples of neoplasms, germ cell and embryonal include:

1. Testicular cancer: This type of cancer develops in the cells of the testes and is most common in young men between the ages of 20 and 35.
2. Ovarian cancer: This type of cancer develops in the cells of the ovaries and is most common in older women.
3. Embryonal carcinoma: This type of cancer develops in the cells that form the embryo during fetal development. It is rare and tends to affect children and young adults.
4. Teratocarcinoma: This type of cancer develops in the cells that form the placenta during pregnancy. It is rare and tends to affect women who have abnormal pregnancies.

Neoplasms, germ cell and embryonal are typically treated with surgery, chemotherapy, or radiation therapy, depending on the location and severity of the cancer. The prognosis for these types of cancers is generally good if they are detected early and treated appropriately. However, if they are not diagnosed and treated promptly, they can spread to other parts of the body and be more difficult to treat.

There are several types of ischemia, including:

1. Myocardial ischemia: Reduced blood flow to the heart muscle, which can lead to chest pain or a heart attack.
2. Cerebral ischemia: Reduced blood flow to the brain, which can lead to stroke or cognitive impairment.
3. Peripheral arterial ischemia: Reduced blood flow to the legs and arms.
4. Renal ischemia: Reduced blood flow to the kidneys.
5. Hepatic ischemia: Reduced blood flow to the liver.

Ischemia can be diagnosed through a variety of tests, including electrocardiograms (ECGs), stress tests, and imaging studies such as CT or MRI scans. Treatment for ischemia depends on the underlying cause and may include medications, lifestyle changes, or surgical interventions.

Pre-B ALL is characterized by the abnormal growth of immature white blood cells called B lymphocytes. These cells are produced in the bone marrow and are normally present in the blood. In Pre-B ALL, the abnormal B cells accumulate in the bone marrow, blood, and other organs, crowding out normal cells and causing a variety of symptoms.

The symptoms of Pre-B ALL can vary depending on the individual patient, but may include:

* Fatigue
* Easy bruising or bleeding
* Frequent infections
* Swollen lymph nodes
* Enlarged liver or spleen
* Bone pain
* Headaches
* Confusion or seizures (in severe cases)

Pre-B ALL is most commonly diagnosed in children, but it can also occur in adults. Treatment typically involves a combination of chemotherapy and sometimes bone marrow transplantation. The prognosis for Pre-B ALL is generally good, especially in children, with a high survival rate if treated promptly and effectively. However, the cancer can be more difficult to treat in adults, and the prognosis may be less favorable.

Overall, Pre-B ALL is a rare and aggressive form of leukemia that requires prompt and specialized treatment to improve outcomes for patients.

Source: National Cancer Institute (www.cancer.gov)

The above definition is given by the National Cancer Institute, which is an authoritative source of information on cancer and lymphoma. It provides a concise overview of follicular lymphoma, including its characteristics, diagnosis, treatment options, and prognosis. The definition includes key terms such as "slow-growing," "B cells," "lymph nodes," and "five-year survival rate," which are important to understand when discussing this type of cancer.

Malignant prostatic neoplasms are cancerous tumors that can be aggressive and spread to other parts of the body (metastasize). The most common type of malignant prostatic neoplasm is adenocarcinoma of the prostate, which accounts for approximately 95% of all prostate cancers. Other types of malignant prostatic neoplasms include sarcomas and small cell carcinomas.

Prostatic neoplasms can be diagnosed through a variety of tests such as digital rectal examination (DRE), prostate-specific antigen (PSA) test, imaging studies (ultrasound, CT scan or MRI), and biopsy. Treatment options for prostatic neoplasms depend on the type, stage, and grade of the tumor, as well as the patient's age and overall health. Treatment options can include active surveillance, surgery (robotic-assisted laparoscopic prostatectomy or open prostatectomy), radiation therapy (external beam radiation therapy or brachytherapy), and hormone therapy.

In summary, Prostatic Neoplasms are tumors that occur in the prostate gland, which can be benign or malignant. The most common types of malignant prostatic neoplasms are adenocarcinoma of the prostate, and other types include sarcomas and small cell carcinomas. Diagnosis is done through a variety of tests, and treatment options depend on the type, stage, and grade of the tumor, as well as the patient's age and overall health.

HIV (human immunodeficiency virus) infection is a condition in which the body is infected with HIV, a type of retrovirus that attacks the body's immune system. HIV infection can lead to AIDS (acquired immunodeficiency syndrome), a condition in which the immune system is severely damaged and the body is unable to fight off infections and diseases.

There are several ways that HIV can be transmitted, including:

1. Sexual contact with an infected person
2. Sharing of needles or other drug paraphernalia with an infected person
3. Mother-to-child transmission during pregnancy, childbirth, or breastfeeding
4. Blood transfusions ( although this is rare in developed countries due to screening processes)
5. Organ transplantation (again, rare)

The symptoms of HIV infection can be mild at first and may not appear until several years after infection. These symptoms can include:

1. Fever
2. Fatigue
3. Swollen glands in the neck, armpits, and groin
4. Rash
5. Muscle aches and joint pain
6. Night sweats
7. Diarrhea
8. Weight loss

If left untreated, HIV infection can progress to AIDS, which is a life-threatening condition that can cause a wide range of symptoms, including:

1. Opportunistic infections (such as pneumocystis pneumonia)
2. Cancer (such as Kaposi's sarcoma)
3. Wasting syndrome
4. Neurological problems (such as dementia and seizures)

HIV infection is diagnosed through a combination of blood tests and physical examination. Treatment typically involves antiretroviral therapy (ART), which is a combination of medications that work together to suppress the virus and slow the progression of the disease.

Prevention methods for HIV infection include:

1. Safe sex practices, such as using condoms and dental dams
2. Avoiding sharing needles or other drug-injecting equipment
3. Avoiding mother-to-child transmission during pregnancy, childbirth, or breastfeeding
4. Post-exposure prophylaxis (PEP), which is a short-term treatment that can prevent infection after potential exposure to the virus
5. Pre-exposure prophylaxis (PrEP), which is a daily medication that can prevent infection in people who are at high risk of being exposed to the virus.

It's important to note that HIV infection is manageable with proper treatment and care, and that people living with HIV can lead long and healthy lives. However, it's important to be aware of the risks and take steps to prevent transmission.

White blood cells are an important part of the immune system, and they help to fight off infections and diseases. A low number of white blood cells can make a person more susceptible to infections and other health problems.

There are several different types of leukopenia, including:

* Severe congenital neutropenia: This is a rare genetic disorder that causes a severe decrease in the number of neutrophils, a type of white blood cell.
* Chronic granulomatous disease: This is a genetic disorder that affects the production of white blood cells and can cause recurring infections.
* Autoimmune disorders: These are conditions where the immune system mistakenly attacks its own cells, including white blood cells. Examples include lupus and rheumatoid arthritis.
* Bone marrow failure: This is a condition where the bone marrow does not produce enough white blood cells, red blood cells, or platelets.

Symptoms of leukopenia can include recurring infections, fever, fatigue, and weight loss. Treatment depends on the underlying cause of the condition and may include antibiotics, immunoglobulin replacement therapy, or bone marrow transplantation.

The prognosis for mantle-cell lymphoma is generally poor, with a five-year survival rate of approximately 40%. Treatment options include chemotherapy, immunotherapy, and autologous stem-cell transplantation. The disease often recurs after initial therapy, and subsequent treatments may be less effective.

Mantle-cell lymphoma can be difficult to distinguish from other types of non-Hodgkin lymphoma, such as follicular lymphoma or diffuse large B-cell lymphoma, and a correct diagnosis is important for determining appropriate treatment.

Slide: Mantle Cell Lymphoma (Image courtesy of Nephron/Wikimedia Commons)

Symptoms of neutropenia may include recurring infections, fever, fatigue, weight loss, and swollen lymph nodes. The diagnosis is typically made through a blood test that measures the number of neutrophils in the blood.

Treatment options for neutropenia depend on the underlying cause but may include antibiotics, supportive care to manage symptoms, and in severe cases, bone marrow transplantation or granulocyte-colony stimulating factor (G-CSF) therapy to increase neutrophil production.

Types of Infection:

1. Bacterial Infections: These are caused by the presence of harmful bacteria in the body. Examples include pneumonia, urinary tract infections, and skin infections.
2. Viral Infections: These are caused by the presence of harmful viruses in the body. Examples include the common cold, flu, and HIV/AIDS.
3. Fungal Infections: These are caused by the presence of fungi in the body. Examples include athlete's foot, ringworm, and candidiasis.
4. Parasitic Infections: These are caused by the presence of parasites in the body. Examples include malaria, giardiasis, and toxoplasmosis.

Symptoms of Infection:

1. Fever
2. Fatigue
3. Headache
4. Muscle aches
5. Skin rashes or lesions
6. Swollen lymph nodes
7. Sore throat
8. Coughing
9. Diarrhea
10. Vomiting

Treatment of Infection:

1. Antibiotics: These are used to treat bacterial infections and work by killing or stopping the growth of bacteria.
2. Antiviral medications: These are used to treat viral infections and work by interfering with the replication of viruses.
3. Fungicides: These are used to treat fungal infections and work by killing or stopping the growth of fungi.
4. Anti-parasitic medications: These are used to treat parasitic infections and work by killing or stopping the growth of parasites.
5. Supportive care: This includes fluids, nutritional supplements, and pain management to help the body recover from the infection.

Prevention of Infection:

1. Hand washing: Regular hand washing is one of the most effective ways to prevent the spread of infection.
2. Vaccination: Getting vaccinated against specific infections can help prevent them.
3. Safe sex practices: Using condoms and other safe sex practices can help prevent the spread of sexually transmitted infections.
4. Food safety: Properly storing and preparing food can help prevent the spread of foodborne illnesses.
5. Infection control measures: Healthcare providers use infection control measures such as wearing gloves, masks, and gowns to prevent the spread of infections in healthcare settings.

AML is a fast-growing and aggressive form of leukemia that can spread to other parts of the body through the bloodstream. It is most commonly seen in adults over the age of 60, but it can also occur in children.

There are several subtypes of AML, including:

1. Acute promyelocytic leukemia (APL): This is a subtype of AML that is characterized by the presence of a specific genetic abnormality called the PML-RARA fusion gene. It is usually responsive to treatment with chemotherapy and has a good prognosis.
2. Acute myeloid leukemia, not otherwise specified (NOS): This is the most common subtype of AML and does not have any specific genetic abnormalities. It can be more difficult to treat and has a poorer prognosis than other subtypes.
3. Chronic myelomonocytic leukemia (CMML): This is a subtype of AML that is characterized by the presence of too many immature white blood cells called monocytes in the blood and bone marrow. It can progress slowly over time and may require ongoing treatment.
4. Juvenile myeloid leukemia (JMML): This is a rare subtype of AML that occurs in children under the age of 18. It is characterized by the presence of too many immature white blood cells called blasts in the blood and bone marrow.

The symptoms of AML can vary depending on the subtype and the severity of the disease, but they may include:

* Fatigue
* Weakness
* Shortness of breath
* Pale skin
* Easy bruising or bleeding
* Swollen lymph nodes, liver, or spleen
* Bone pain
* Headache
* Confusion or seizures

AML is diagnosed through a combination of physical examination, medical history, and diagnostic tests such as:

1. Complete blood count (CBC): This test measures the number and types of cells in the blood, including red blood cells, white blood cells, and platelets.
2. Bone marrow biopsy: This test involves removing a small sample of bone marrow tissue from the hipbone or breastbone to examine under a microscope for signs of leukemia cells.
3. Genetic testing: This test can help identify specific genetic abnormalities that are associated with AML.
4. Immunophenotyping: This test uses antibodies to identify the surface proteins on leukemia cells, which can help diagnose the subtype of AML.
5. Cytogenetics: This test involves staining the bone marrow cells with dyes to look for specific changes in the chromosomes that are associated with AML.

Treatment for AML typically involves a combination of chemotherapy, targeted therapy, and in some cases, bone marrow transplantation. The specific treatment plan will depend on the subtype of AML, the patient's age and overall health, and other factors. Some common treatments for AML include:

1. Chemotherapy: This involves using drugs to kill cancer cells. The most commonly used chemotherapy drugs for AML are cytarabine (Ara-C) and anthracyclines such as daunorubicin (DaunoXome) and idarubicin (Idamycin).
2. Targeted therapy: This involves using drugs that specifically target the genetic abnormalities that are causing the cancer. Examples of targeted therapies used for AML include midostaurin (Rydapt) and gilteritinib (Xospata).
3. Bone marrow transplantation: This involves replacing the diseased bone marrow with healthy bone marrow from a donor. This is typically done after high-dose chemotherapy to destroy the cancer cells.
4. Supportive care: This includes treatments to manage symptoms and side effects of the disease and its treatment, such as anemia, infection, and bleeding. Examples of supportive care for AML include blood transfusions, antibiotics, and platelet transfusions.
5. Clinical trials: These are research studies that involve testing new treatments for AML. Participating in a clinical trial may give patients access to innovative therapies that are not yet widely available.

It's important to note that the treatment plan for AML is highly individualized, and the specific treatments used will depend on the patient's age, overall health, and other factors. Patients should work closely with their healthcare team to determine the best course of treatment for their specific needs.

Benign ovarian neoplasms include:

1. Serous cystadenoma: A fluid-filled sac that develops on the surface of the ovary.
2. Mucinous cystadenoma: A tumor that is filled with mucin, a type of protein.
3. Endometrioid tumors: Tumors that are similar to endometrial tissue (the lining of the uterus).
4. Theca cell tumors: Tumors that develop in the supportive tissue of the ovary called theca cells.

Malignant ovarian neoplasms include:

1. Epithelial ovarian cancer (EOC): The most common type of ovarian cancer, which arises from the surface epithelium of the ovary.
2. Germ cell tumors: Tumors that develop from germ cells, which are the cells that give rise to eggs.
3. Stromal sarcomas: Tumors that develop in the supportive tissue of the ovary.

Ovarian neoplasms can cause symptoms such as pelvic pain, abnormal bleeding, and abdominal swelling. They can also be detected through pelvic examination, imaging tests such as ultrasound and CT scan, and biopsy. Treatment options for ovarian neoplasms depend on the type, stage, and location of the tumor, and may include surgery, chemotherapy, and radiation therapy.

... , also known as rescue therapy, is a form of therapy given after an ailment does not respond to standard therapy ... Salvage therapy drugs or drug combinations have, in general, much more severe side effects than the standard line of therapy. ... "Antiretroviral Therapy (ART)". World Health Organization. 2006. Retrieved 2006-10-26. "SALVAGE THERAPY". The AIDS InfoNet. 2006 ... Heroic measure Linda Grinberg "Definition of Salvage therapy". MedicineNet.com. 2006. Retrieved 2006-10-26. "HIV Therapy 2006 ...
Wedemeyer, Christian; Kauther, Max Daniel (2011-03-16). "Hemipelvectomy- only a salvage therapy?". Orthopedic Reviews. 3 (1): ...
SIRT is currently considered as a salvage therapy. It has been shown to be safe and effective in patients for whom surgery is ... establishing the safety of the therapy. More recently, larger trials and RCTs have shown safety and efficacy of 90Y therapy for ... Radiation therapy is used to kill cancer cells; however, normal cells are also damaged in the process. Currently, therapeutic ... "Sorafenib and Micro-therapy Guided by Primovist Enhanced MRI in Patients With Inoperable Liver Cancer - Full Text View - ...
He also introduced drug development strategies for salvage therapy, and discussed the conflicts and solutions regarding this. ... "Drug development strategies for salvage therapy: conflicts and solutions". AIDS Research and Human Retroviruses. 22 (11): 1106- ... He has also authored several books and textbooks, including Protease Inhibitors in AIDS Therapy, Integrative Pharmacology, ... Comparison of once-daily versus twice-daily combination antiretroviral therapy in treatment-naïve patients: results of AIDS ...
Fuzeon (enfuvirtide), for salvage therapy of HIV-1 infection. Gazyva (obinutuzumab), for chronic lymphocytic leukemia. Hemlibra ... A second gene therapy-related action came in December with the US$1.15 billion acquisition of non-United States rights to an ... In 1995 the era of highly active anti-retroviral therapy (HAART) was initiated by the United States FDA's approval of Hoffman ... "Roche 'steps up' for gene therapy with $4.3 billion Spark bet". Reuters.com. Reuters. 25 February 2019. "Roche says its $4.3 ...
It is not considered a first-line treatment, but it can be useful as salvage therapy. It also has the advantage of being less ... Chan JK, Loizzi V, Manetta A, Berman ML (2004). "Oral altretamine used as salvage therapy in recurrent ovarian cancer". Gynecol ... Malik IA (2001). "Altretamine is an effective palliative therapy of patients with recurrent epithelial ovarian cancer". Jpn. J ... a single agent in the palliative treatment of patients with persistent or recurrent ovarian cancer following first-line therapy ...
"Confronting an Unaddressed Nigerian Reality in the Exhibition 'Salvage Therapy' , By Ayò Akínwándé". The Sole Adventurer. 2018- ... 2018 Confronting an Unaddressed Nigerian Reality in the Exhibition 'Salvage Therapy' The Sole Adventurer. 2020 "Who Art ...
When primary or secondary resistance invariably develops, salvage therapy is considered. Allogeneic stem cell transplantation ... They recommended starting therapy in patients with constitutional symptoms such as recurrent fever, night sweats, fatigue due ... Gertz MA (2005). "Waldenstrom macroglobulinemia: a review of therapy". Am J Hematol. 79 (2): 147-57. doi:10.1002/ajh.20363. ... However, CXCR4 mutation is not associated with splenomegaly, high platelet counts, or different response to therapy, ...
She served on the board of Project Inform, was founder of the Coalition for Salvage Therapy, co-founder of the FAIR Pricing ... James, John S. (November 5, 1999). "Activism today: the Coalition for Salvage Therapy: Interview with Linda Grinberg". AIDS ... concerned for expediting new treatments for AIDS and ensuring access to experimental therapies, especially for late-stage ...
August 2001). "Mito-flag as salvage therapy for relapsed and refractory acute myeloid leukemia". Onkologie. 24 (4): 356-60. doi ...
Summerfield DT, Desai H, Levitov A, Grooms DA, Marik PE (2011). "Inhaled Nitric Oxide as Salvage Therapy in Massive ... Nitric oxide is also administered as salvage therapy in patients with acute right ventricular failure secondary to pulmonary ... It is used on an individualized basis in ICUs as an adjunct to other definitive therapies for reversible causes of hypoxemic ... This research is based on the fact that nitric oxide was investigated as an experimental therapy for SARS. Brian Strickland, MD ...
other antibiotics, such as minocycline, have seen some use as a salvage therapy). If infected during pregnancy, spiramycin is ... Combination therapy is most useful in the setting of HIV. Clindamycin Spiramycin - an antibiotic used most often for pregnant ... As a result, the possibility of an alternate diagnosis is supported by a failed trial of antimicrobial therapy (pyrimethamine, ... an antibiotic used in combination with pyrimethamine to treat toxoplasmosis Combination therapy is usually given with folic ...
Per Montag's request to salvage their relationship, Pratt agreed to attend couples' therapy. As they became re-engaged and ...
The treatments include surgery, chemotherapy, radiation therapy, targeted therapy, salvage therapy, and clinical trials. Among ... Salvage Therapy: this treatment is given if there is no response to previous treatments. Clinical Trials: the follow up study ... February 2014). "Salvage therapy for refractory or recurrent pediatric germ cell tumors: the French SFCE experience". Pediatric ... "Radiation Therapy". National Cancer Institute. 2015-04-29. Retrieved 2019-05-27. "Understanding Targeted Therapy". Cancer.Net. ...
van Burik JA, Hare RS, Solomon HF, Corrado ML, Kontoyiannis DP (2006). "Posaconazole is effective as salvage therapy in ... analysis of infectious complications in patients treated with T cell depletion versus immunosuppressive therapy to prevent ...
Intraoperative radiation therapy and Intraoperative blood salvage may also be performed during this time. The postoperative ...
2006). "Foscarnet salvage therapy for patients with late-stage HIV disease and multiple drug resistance". Antivir. Ther. (Lond ... Foscarnet can be used to treat highly treatment-experienced patients with HIV as part of salvage therapy. Foscarnet is a ... 2007). "Long-term foscarnet therapy remodels thymidine analogue mutations and alters resistance to zidovudine and lamivudine in ...
"Refractory Craniofacial Actinomycetoma Due to Streptomyces somaliensis That Required Salvage Therapy with Amikacin and Imipenem ...
... and Salvage Radiation Therapy for Cutaneous Squamous Cell Carcinoma". Dermatologic Surgery. 47 (5): 587-592. doi:10.1097/DSS. ... Radiation therapy is often used afterward in high risk cancer or patient types. Radiation or radiotherapy can also be a ... Radiotherapy Adjuvant therapy may be considered in those with high-risk SCC even in the absence of evidence for local ... An example of this kind of therapy is the High dose brachytherapy Rhenium-SCT which makes use of the beta rays emitting ...
"Clarithromycin-Minocycline Combination as Salvage Therapy for Toxoplasmosis in Patients Infected with Human Immunodeficiency ... Occasionally, minocycline therapy may result in autoimmune disorders such as drug-related lupus and autoimmune hepatitis, which ... Autoimmune problems emerge during chronic therapy, but can sometimes occur after only short courses of a couple of weeks of ... Drug reaction with eosinophilia and systemic symptoms syndrome can occur during the first few weeks of therapy with minocycline ...
Small studies have also examined its use as salvage therapy for non-tuberculous mycobacterial infections. It is a component of ... BPaMZ @ TB Alliance Archived 2017-02-19 at the Wayback Machine Two new drug therapies might cure every form of tuberculosis. ...
Voriconazole is also being studied in salvage therapy for refractory cases. A case report indicated that voriconazole in ... Posaconazole has been approved by the European Commission as a salvage therapy for refractory coccidioidomycosis. Clinical ... The duration of therapy is dictated by the clinical course of the illness, but it should be at least 6 months in all patients ... Therapy is tailored based on a combination of resolution of symptoms, regression of radiographic abnormalities, and changes in ...
These include: Visual Representations: Past and Present Artist-At-Work Artist Talk Salvage Art Therapy Exhibition. Power Show ...
"Amsacrine combined with etoposide and high-dose methylprednisolone as salvage therapy in acute lymphoblastic leukemia in ...
... may delay cell death and allow for greater salvage of myocardium through reperfusion therapy. AICAR has been shown to ... as a targeting agent for therapy of patients with acute lymphoblastic leukemia: are we there and are there pitfalls?". Journal ...
Lutz M, Kapp M, Grigoleit GU, Stuhler G, Einsele H, Mielke S (April 2012). "Salvage therapy with everolimus improves quality of ... Interim phase III trial results in 2011, showed that adding Afinitor (everolimus) to exemestane therapy against advanced breast ... and mTOR inhibition has been suggested as an anti-aging therapy. Everolimus was used in a clinical trial by Novartis, and short ... is a medication used as an immunosuppressant to prevent rejection of organ transplants and as a targeted therapy in the ...
Like lopinavir and atazanavir, it is very potent and is effective in salvage therapy for patients with drug resistance. However ... It is administered with ritonavir in combination therapy to treat HIV infection.[citation needed] Tipranavir has the ability to ...
They are also useful in salvage therapy for patients whose virus has mutated and acquired resistance to other drugs.[citation ... "raltegravir plus optimized background therapy provided better viral suppression than optimized background therapy alone for at ... USA (2014). "Antiretroviral Therapy: Current Drugs". Infectious Disease Clinics of North America. Ncbi.nlm.nih.gov. 28 (3): 371 ... July 2008). "Raltegravir with optimized background therapy for resistant HIV-1 infection". N. Engl. J. Med. 359 (4): 339-54. ...
Caspofungin is used in the treatment of febrile neutropenia and as "salvage" therapy for the treatment of invasive ...
It is used in select situations, for instance as a salvage therapy in severe complicated cases or in other situations. One ... Kim C, Catanzariti AR, Mendicino RW (April 2009). "Tibiotalocalcaneal arthrodesis for salvage of severe ankle degeneration". ...
... may be performed to salvage the potential life. EXIT technique involves partial delivery of a baby through an incision in the ... therapy/fetal-interventions-procedures/ex_utero_intrapartum_t reatment.html Sadiqi, Jamshid; Hamidi, Hidayatullah (October 30, ... Johns Hopkins Center for Fetal Therapy in Baltimore, Md. (May 7, 2019). Retrieved April 4, 2020, from https://www. ...
... the practice of salvaging a record of what was left of a culture before it disappeared Salvage therapy, medical treatment for ... Salvage may refer to: Marine salvage, the process of rescuing a ship, its cargo and sometimes the crew from peril Water salvage ... "salvage" Salvage for Victory, a US Government campaign to salvage materials for the American war effort in World War II Paper ... "Salvage" (Angel), a 2003 episode of the television series Angel Salvage, a 1962 episode in the Hallmark Hall of Fame Salvage ( ...
Non-surgical treatment may involve radiation therapy, chemotherapy, hormonal therapy, external beam radiation therapy, and ... Mouraviev V, Evans B, Polascik TJ (2006). "Salvage prostate cryoablation after primary interstitial brachytherapy failure: a ... Hormonal therapy is used for some early-stage tumors. Cryotherapy (the process of freezing the tumor), hormonal therapy, and ... Such therapies could provide an advantage; particularly in treating prostate cancers that are resistant to current therapies. ...
Elsewhere, combat stages are often salvaged from abandoned buildings and private woodland. Many of the larger playfields are ... The movement of troops among the cacophony of heavy machines provides an immersive sensory environment for exposure therapy. ...
Mary Burd, lately Director of Therapies, East London and City Mental Health Trust and Head of Psychology, Tower Hamlets. For ... Robin Ernest Vincent Middleton, lately Secretary of State's Representative for Salvage and Intervention, Department for ... Edward Major, lately Clinical Director, Intensive Therapy Unit, Swansea. For services to the NHS. Rosemary Manning. For ...
and its Dominion Salvage campaign did not commence until April 1941. The importance of salvage was not so much that there was a ... Facilities for physio- and occupational therapy were available when recommended by the physician. Trainees received $50 a month ... The head of the American waste paper salvage wrote, "we have come to recognize Amity as the most efficient example of a salvage ... The salvage campaign soon became known to its federal counterpart. Visitors from all parts of Canada were sent to study Amity's ...
"Cell Saver (Intraoperative Cell Salvage Machine)". University of Southern California Keck School of Medicine. Retrieved 2012-02 ... Respiratory Therapy (CRT or RRT) Surgery (CST) Currently, the International Board of Blood Management is the governing body for ...
Those who were abroad at the outbreak of war or who managed to escape set about salvaging their heritage outside Poland. During ... Margaret Lowenfeld (1890-1973) - physician and pioneer of Play therapy Bronisław Malinowski (1884-1942) - one of the most ...
McPhail GL, Clancy JP (April 2013). "Ivacaftor: the first therapy acting on the primary cause of cystic fibrosis". Drugs of ... salvage transporter human Na+-HCO3- cotransport isoform 3". The Journal of Biological Chemistry. 277 (52): 50503-50509. doi: ... De Boeck K, Amaral MD (August 2016). "Progress in therapies for cystic fibrosis". The Lancet. Respiratory Medicine. 4 (8): 662- ... Retrieved 2 August 2017.[permanent dead link] Guimbellot J, Sharma J, Rowe SM (November 2017). "Toward inclusive therapy with ...
After intense physical therapy, Alvarez made the United States' World Cup Team in December 2012. He finished the season as the ... speedskaters salvage a medal". Miami Herald. Retrieved March 2, 2014. "White Sox sign Olympic speedskater to minor deal". SI. ... While his teammates worked on their skating skills, he underwent intense physical therapy to rehabilitate his leg muscles. By ...
Mitte stated he had to regress from his therapy to portray the character, staying up late into the night to slur his speech and ... 9.72 million he had managed to salvage for her and the children. Jesse's loneliness in the early seasons of the show can be ...
Not willing to lose his empire, he caused a fire in attempt to salvage his investments, but it resulted in several lives. He ... When the family learned of his situation, the youngest brother, Kwan Ka-Wing (Him Law), decided to pitch in with his therapy ...
Played by Sam Underwood, Leo Carras is Dana's boyfriend who she meets while in therapy. After Dana is released, she continues ... thereby ending Keane's hopes of salvaging her administration. After Simone is successfully exfiltrated and testifies regarding ... Now completely demoralized, she submits herself to electroconvulsive therapy as she is no longer confident in her skills. When ... but is able to manage it more effectively than his daughter due to his commitment to therapy and medication. Frank eventually ...
For services to Salvage and Underwater Heritage. Richard Anthony Kerslake. For services to Education and to the Arts in the ... Nigel James Miller, Head of Therapies, Learning Disabilities Services, Hywel Dda University Health Board. For services to ...
David Fury (writer), Jefferson Kibbee (director) (2003-03-05). "Salvage". Angel. Season 4. Episode 13. The WB. Mere Smith ( ... Using the Television Program Buffy the Vampire Slayer in Adolescent Therapy and Psychodynamic Education". Academic Psychiatry. ... "Salvage", and magically battles former friend Willow to keep Angel from his soul in the episode "Orpheus". In season four's " ...
Two weeks earlier, a girl whom Sweitat had salvaged from a school classroom that had just been bombed by the IDF died as he ... up a children's center to teach over 1500 children in the Jenin camp and asked her son to join her there to teach drama therapy ...
... most of which were salvaged by the British after the battle. Battle of Nebi Samwil - The British 75th Infantry Division ... known for his promotion of megavitamin therapy to treat schizophrenia (d. 2009); Tippy Larkin, American boxer, world light ...
When the salvaging company goes out of business due to the Department of Damage Control, Mason helps Toomes steal leftover ... Walker later assists Barnes after he is arrested for missing court-mandated therapy and again is refused when he asks Barnes ... Phineas Mason (portrayed by Michael Chernus) is a weapons maker and part of a salvage company alongside Adrian Toomes, Herman ... is a former salvage worker and professional criminal. When Jackson Brice is killed, Schultz assumes the Shocker mantle and ...
Later, he attempts to salvage what he can from the destroyed offices of the Chada Trading Company to prevent any potential ... two of the clones are dead and the others show little sign of responding to therapy. When Alex encountered him, Grief was ...
Research comparing endodontic therapy with implant therapy is considerable, both as an initial treatment and in retreatment for ... endodontic treatments as well as periradicular surgery which is generally used for teeth that still have potential for salvage ... Root canal treatment (also known as endodontic therapy, endodontic treatment, or root canal therapy) is a treatment sequence ... Root canal therapy has become more automated and can be performed faster thanks in part to machine-driven rotary technology and ...
The band continued to pursue the tour themselves and managed to salvage 8 dates. The band recruited new bass player Jette Pille ... 2012 also so the band tour alongside the likes of Therapy?, Kerbdog, and Shonen Knife. In August 2011, shortly after Corporate ...
Abrams, Natalie (September 7, 2017). "The Flash: Barry and Iris heading to couples therapy". Entertainment Weekly. Archived ... wasn't really enough to salvage the season." In a more positive review from The A.V. Club, Scott Von Doviak gave the finale a ... while also revealing that the pair will be going to couples therapy since "[they] keep comically clashing inadvertently because ...
An architectural salvage and antique yard, Kilkenny Architectural Salvage, is currently located on the site. Kilkenny is a ... It also provides paediatric physiotherapy, and occupational therapy. Kilcreene is the regional orthopaedic hospital outside the ... "About Kilkenny Architectural Salvage & Antiques". eurosalve.com. Archived from the original on 15 June 2020. Retrieved 15 June ...
... is an acronym for relatively intensive chemotherapy regimen that is used for salvage therapy in relapsed or refractory ...
Gene therapy vectors (such as viruses) can be PEG-coated to shield them from inactivation by the immune system and to de-target ... PEG is frequently used to preserve waterlogged wood and other organic artifacts that have been salvaged from underwater ... PEG is used in medicines for treating disimpaction and maintenance therapy for children with constipation. When attached to ... PEGylation of adenoviruses for gene therapy can help prevent adverse reactions due to pre-existing adenovirus immunity. A ...
At a therapy session in Taos, he reveals he now owns a therapy dog named Wingman and is on the road to recovery from his trauma ... In the episode "Salvage", it is revealed that Roy married Cheshire and unknowingly fathered a daughter with her. Cheshire is ... While in therapy with Black Canary, Virgil unknowingly displays his manifested electrical powers when a bunch of paper clips ... After an intervention involving Miss Martian, the Outsiders, and Robotman fails to shake him, therapy with Black Canary reveals ...
No program which employs drug or electric shock therapy was presented, as it has been discovered that groups which condone ... They both enlighten and generate new activities: from salvaging lives from illiteracy, addiction [Narconon] and crime; to ... The program's purpose was to discover whether Hubbard's program has a scientific basis for therapy and whether it was effective ... The cover organization, Narconon, offers drug rehabilitation therapy that, in the opinion of experts and doctors in the field, ...
The objective of this study was to describe the efficacy of zidovudine as modern day salvage antiretroviral therapy. This was a ... Zidovudine as modern day salvage therapy for HIV infection Katherine E Kupiec 1 , James W Johnson, Luis F Barroso, Rebekah H ... Zidovudine as modern day salvage therapy for HIV infection Katherine E Kupiec et al. AIDS Patient Care STDS. 2014 Nov. ... The objective of this study was to describe the efficacy of zidovudine as modern day salvage antiretroviral therapy. This was a ...
However, even with prompt induction of intravesical therapy, approximately 40 % of patients will recur within 2 years. ... receive intravesical therapy with bacillus Calmette-Guérin (BCG) as the well-established standard-of-care. ... For patients who fail BCG, options include radical cystectomy, repeat BCG therapy, or alternative intravesical salvage therapy ... Experience with Sequential Intravesical Gemcitabine and Docetaxel as Salvage Therapy for Non-Muscle Invasive Bladder Cancer ...
Defining the index lesion for potential salvage partial or hemi-gland ablation after radiation therapy for localized prostate ... Defining the index lesion for potential salvage partial or hemi-gland ablation after radiation therapy for localized prostate ... prospective studies are required to evaluate both the role of MRI and clinical criteria in guiding focal salvage therapy and ... Salvage partial gland ablation (sPGA) has been proposed to treat some localized radiorecurrent prostate cancer. The role of ...
Posaconazole as salvage therapy for zygomycosis.. R N Greenberg, K Mullane, J-A H van Burik, I Raad, M J Abzug, G Anstead, R ... multicentered compassionate trials that evaluated oral posaconazole as salvage therapy for invasive fungal infections. ... in 19 subjects with zygomycosis refractory to standard therapy and 80% in 5 subjects with intolerance to standard therapy. ... Duration of posaconazole therapy ranged from 8 to 1,004 days (mean, 292 days; median, 182 days). Rates of successful treatment ...
Salvage therapy for castration-refractory prostate cancer resistant to docetaxel]. [Salvage therapy for castration-refractory ... Salvage treatments include DTX (30 mg/m2) + cisplatin (CDDP) (70 mg/m2)/carboplatin (Area under the curve = 4), etoposide + ... All salvage treatments without grade 4 toxicities described in this study may be acceptable in the patients with CRPC ... The reasons why 14 patients moved to salvage treatments after DTX were progressive disease in 12 patients and adverse events in ...
SALVAGE THERAPY. TUMOR CELLS, CULTURED and indentions. TUMOR MARKERS, BIOLOGICAL and indentions. ...
Staphylococcus aureus, Pseudomonas aeruginosa, Klebsiella pneumoniae bacteremia; recent interferon-α therapy; salvage ...
Does salvage radiation therapy change the biology of recurrent prostate cancer based on PSA doubling times? Results from the ... Does salvage radiation therapy change the biology of recurrent prostate cancer based on PSA doubling times? Results from the ... Does salvage radiation therapy change the biology of recurrent prostate cancer based on PSA doubling times? Results from the ... Does salvage radiation therapy change the biology of recurrent prostate cancer based on PSA doubling times? Results from the ...
Postoperative photodynamic therapy as a new adjuvant treatment after robot-assisted salvage surgery of recurrent squamous cell ...
12 months in first salvage or relapsed or refractory after first salvage therapy or relapsed within 12 months of alloHSCT, and ... 35 years of age), prior salvage therapy (yes vs. no), and prior alloHSCT (yes vs. no) as assessed at the time of consent. The ... had received more than 2 prior salvage therapies.. Efficacy was based on the complete remission (CR) rate, duration of CR, and ... blasts in the bone marrow and refractory to primary induction therapy or refractory to last therapy, untreated first relapse ...
... highly active antiretroviral therapies (HAART), or at the point of treatment failure when so-called "salvage therapies" are ... initiation of salvage therapies).. *Inform future studies to identify effective strategies for optimal suppression of alcohol ... trials are the COMBINE Medical Management Therapy and the Brief Behavioral Compliance Enhancement Treatment (BBCET) Therapy. To ... The therapy should also help the patient set a goal to either become abstinent or cut down to a safe level of drinking. Two ...
The best management strategy for HIV patients who fail to respond to first-line therapy for Pneumocystis jirovecii pneumonia is ... The best management strategy for HIV patients who fail to respond to first-line therapy for Pneumocystis jirovecii pneumonia is ... Trimetrexate and folinic acid: a valuable salvage option for Pneumocystis jirovecii pneumonia Charlotte-Eve S Short 1 , Yvonne ... Trimetrexate and folinic acid: a valuable salvage option for Pneumocystis jirovecii pneumonia Charlotte-Eve S Short et al. AIDS ...
Previous salvage therapies after first recurrence are permitted.. *Measurable contrast-enhancing progressive or recurrent GBM ( ... TAU-2014-1: Mibefradil and Hypofractionated Re-Irradiation Therapy in Recurrent GBM. The safety and scientific validity of this ... Radiation therapy (RT) consists of 5 fractions of 600 centigray (cGy) each, delivered over 2 consecutive weeks for a total dose ... TAU-2014-1: Phase I Trial of Mibefradil Dihydrochloride With Hypofractionated Re-Irradiation Therapy in Treating Patients With ...
Clinical Outcomes and Salvage Therapies in Patients With Relapsed/Refractory Multiple Myeloma Following Progression on BCMA- ... from time of PD and types of salvage regimens utilized including ORR and treatment duration for subsequent line therapies. ... The researchers performed a single-center retrospective analysis of RRMM patients who received any BCMA CAR-T therapy between ... Despite achieving a deep hematologic response after therapy, systemic light-chain amyloidosis (AL) patients may not attain an ...
Salvage brachytherapy. Recurrent disease and residual disease after therapy are fairly common in patients with prostate cancer ... Salvage brachytherapy. Salvage high-dose brachytherapy has been successfully used in patients with local macroscopic relapse in ... Over the past few years, salvage brachytherapy has been increasingly advocated as a therapeutic option in addition to salvage ... For high-risk patients, combination therapies involving EBRT and brachytherapy plus or minus androgen deprivation therapy ...
Salvage Treatment use Salvage Therapy Salvage Treatments use Salvage Therapy Salvage, Intraoperative Blood use Operative Blood ... Salvage Therapies use Salvage Therapy Salvage Therapy ... Salvage, Limb use Limb Salvage Salvage, Operative Blood use ... Salvage, Post-Operative Blood use Operative Blood Salvage Salvage, Postoperative Blood use Operative Blood Salvage ...
Liver transplantation has become accepted therapy for several causes of irreversible liver disease. Indications The most common ... Roberts SK, Kemp W. Salvage therapies for autoimmune hepatitis: a critical review. Semin Liver Dis. 2017 Nov. 37(4):343-62. [ ... Alternative therapies include antibody treatments such as monoclonal therapy with rabbit antithymocyte globulin or OKT3 ( ... Studies have shown that dual therapy with steroids and a calcineurin inhibitor are just as efficacious as triple therapy while ...
Potential salvage therapy for inadvertent intrathecal administration of vincristine. Br. J. Haematology, 1997; 99: 364-367. ( ... Following therapy with vinblastine sulfate, the nadir in white blood cell count may be expected to occur five to ten days after ... It is wise to initiate therapy for adults by administering a single intravenous dose of 3.7 mg/m 2 of body surface area (bsa). ... Such combination therapy produces a greater percentage of response than does a single-agent regimen. These principles have been ...
Lopinavir plasma concentrations and changes in lipid levels during salvage therapy with lopinavir/ritonavir-containing regimens ... Recommended values of LDL-C and non-HDL-C at which to initiate therapeutic lifestyle changes and/or drug therapy, as well as ... We defined the HDL-C value below which to initiate lipid-modifying therapy and at or above which we considered goal to have ... Efficacy and safety of tenofovir DF vs stavuine in combination therapy in antiretroviral-naive patients: a 3-year randomized ...
Lack of PSA Decline as an Independent Predictor of Biochemical Failure Post Salvage Radiation Therapy. It would be of great ... salvage therapy, Surgery, Uncategorized, United Kingdom - England, Northern Ireland, Scotland & Wales,1 Comment ... but little is known about its potential clinical application in the use of early salvage radiotherapy after failed radical ... advantage to us if we were able to improve the early detection of responders to salvage external beam radiotherapy (RT) after ...
Combination therapy of rituximab with nucleoside analogs has been investigated as both first-line and salvage therapy by Laszlo ... the following treatment algorithms as depicted in Figure 3 for first-line and salvage therapy can be suggested, implying that ... Fludarabine combination therapy is highly effective in first-line and salvage treatment of patients with Waldenstroms ... Rituximab single-agent therapy is less effective in WM than in follicular lymphoma and 4 weekly infusions of rituximab achieve ...
Salvage stereotactic radiosurgery effectively treats recurrences from whole-brain radiation therapy. Cancer. 2008 Oct.113(8): ... Primary medical therapy for BRAF-mutant melanoma brain metastases-is this good enough?. Lancet Oncol. 2017 Sep.18(9):e508. ... Targeted Therapies for Brain Tumors: Will They Ever Deliver?. Clin Cancer Res. 2018 Aug.24(16):3790-3791. Pubmedid: 29798907. ... Evidence-based adjuvant therapy for gliomas: current concepts and newer developments. Indian J Cancer. 2009 Apr.46(2):96-107. ...
R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: the influence of prior ... Salvage therapy in Hodgkins lymphoma.. Mendler JH; Friedberg JW. Oncologist; 2009 Apr; 14(4):425-32. PubMed ID: 19342476. [TBL ... 8. High-dose therapy and autologous stem cell transplantation for follicular lymphoma undergoing transformation to diffuse ... for high-risk lymphoma patients treated with hematopoietic stem cell transplantation as consolidation or salvage therapy. ...
Technetium-99m Sestamibi for the Assessment of Myocardial Salvage Following Reperfusion Therapy in Acute Myocardial Infarction ... Reperfusion therapy for acute myocardial infarction is feasible with thrombolytic therapy as well as acute percutaneous ... Medical Therapy in Heart Failure - Is Polypharmacy Necessary?. BWK Kwok The clinical syndrome of heart failure is recognised by ... Ablation therapies for paroxysmal atrial fibrillation: A systematic review and patient-level network meta-analysis. Khi Yung ...
The lowest cost of a third-line drug regime - or salvage therapy - in Africa is $1,859 a person annually. ... not just because of the increase in infections and the fact that everybody must take antiretroviral therapy for life, but also ...
... salvage,salvage,1152,1,Gn,1, salvage,salvage therapies,128,8,Gn,1, salvage,salvage therapy,128,1,Gn,1, salvage,salvageability, ... 128,1,Gn,1, salvage,salvageable,1,1,Gn,1, salvage,salvaged,1024,32,Gn,1, salvage,salvages,1024,128,Gn,1, salvage,salvaging,1024 ...
Blue Star: vintage signage, Sarasota Architectural Salvage. Swinging chair: Habitat (uk). Space fabric: Osborne & Little. ... Apartment Therapy. is a part of the AT Media family. AT Media is. Apartment Therapy,. Kitchn, and. Cubby. ... Interested in sharing your home with Apartment Therapy? Contact the editors through our House Tour Submission Form. ...
R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: the influence of prior ... Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP). Blood. 1988 ... Olivieri A, Brunori M, Capelli D, Montanari M, Massidda D, Gini G. Salvage therapy with an outpatient DHAP schedule followed by ... Rituximab-EPOCH, an effective salvage therapy for relapsed, refractory or transformed B-cell lymphomas: results of a phase II ...
BM with evidence of persistent leukemia 5-10% blasts post induction/salvage therapy. Patients with BM blast count , 10% may ... FDA-approved therapies under investigation for alternative uses are permitted. 10. Donors deemed not medically suitable per the ... Currently not requiring systemic corticosteroid therapy (10 mg or less of prednisone or equivalent doses of other systemic ... 9. Donors receiving experimental therapy or investigational agents within 30 days of the start of conditioning. ...
  • Defining the index lesion for potential salvage partial or hemi-gland ablation after radiation therapy for localized prostate cancer. (nih.gov)
  • Does salvage radiation therapy change the biology of recurrent prostate cancer based on PSA doubling times? (elsevierpure.com)
  • Objective: To investigate whether salvage radiation therapy (SRT) may promote prostate cancer (PCa) transformation to more aggressive phenotypes. (elsevierpure.com)
  • Dive into the research topics of 'Does salvage radiation therapy change the biology of recurrent prostate cancer based on PSA doubling times? (elsevierpure.com)
  • Brachytherapy candidates with a significant risk of extraprostatic extension should be treated with supplemental intensity-modulated radiation therapy. (medscape.com)
  • Interest in brachytherapy waned in the early 1980s because of these results, the advent of more advanced external beam radiation therapy (EBRT) equipment, and the development of the nerve-sparing radical prostatectomy. (medscape.com)
  • Along with radical prostatectomy , cryotherapy , and EBRT (also referred to as intensity-modulated radiation therapy [ IMRT ]), interstitial brachytherapy is a potentially curative treatment for localized prostate cancer. (medscape.com)
  • This is a dose-escalation study that will assess the safety and determine the maximum tolerated dose (MTD) of mibefradil dihydrochloride, a partially selective T-type calcium channel blocker, combined with hypofractionated radiation therapy (RT) in subjects with recurrent glioblastoma multiforme (GBM). (clinicaltrials.gov)
  • Radiation therapy (RT) consists of 5 fractions of 600 centigray (cGy) each, delivered over 2 consecutive weeks for a total dose of 3,000 cGy, using stereotactic, intensity-modulated radiation therapy (IMRT). (clinicaltrials.gov)
  • This will be given concurrently with hypofractionated radiation therapy. (clinicaltrials.gov)
  • A therapeutic approach, involving chemotherapy, radiation therapy, or surgery, after initial regimens have failed to lead to improvement in a patient's condition. (nih.gov)
  • In this review, we will discuss the most recent published evidence on salvage intravesical therapy with an emphasis on a more in-depth report of our therapeutic strategy with sequential gemcitabine and docetaxel intravesical therapy for this treatment-refractory population. (urotoday.com)
  • Rates of successful treatment (complete cure and partial response) were 79% in 19 subjects with zygomycosis refractory to standard therapy and 80% in 5 subjects with intolerance to standard therapy. (qxmd.com)
  • Salvage therapy for castration-refractory prostate cancer resistant to docetaxel]. (bvsalud.org)
  • 17. R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: the influence of prior exposure to rituximab on outcome. (nih.gov)
  • 32. Cisplatin and ifosfamide with either vinblastine or etoposide as salvage therapy for refractory or relapsing germ cell tumor patients: the Institut Gustave Roussy experience. (nih.gov)
  • These results suggest ECMO may be an important salvage therapy for individuals with refractory asthma exacerbations with respiratory failure. (chestnet.org)
  • liso-cel), a CD19-directed chimeric antigen receptor (CAR) T cell therapy, for the treatment of adult patients with diffuse large B-cell lymphoma (DLBCL), high grade B-cell lymphoma (HGBCL), primary mediastinal large B-cell lymphoma (PMBCL) and follicular lymphoma grade 3B (FL3B), who relapsed within 12 months from completion of, or are refractory to, first-line chemoimmunotherapy. (yahoo.com)
  • With Breyanzi, people in Europe living with relapsed or refractory DLBCL now have a differentiated CAR T cell therapy option earlier in the treatment paradigm that provides long-term clinical benefit,' said Anne Kerber, senior vice president, head of Cell Therapy Development, Bristol Myers Squibb. (yahoo.com)
  • In DLBCL, the most common form of non-Hodgkin lymphoma, up to 40% of patients have disease that is refractory to or relapses following initial therapy. (yahoo.com)
  • 28. [Results of chemotherapy and salvage surgery for advanced testicular cancer]. (nih.gov)
  • 38. Early salvage therapy for germ cell cancer using high dose chemotherapy with autologous bone marrow support. (nih.gov)
  • The standard therapy for these patients consists of intensive salvage immunochemotherapy followed by high-dose chemotherapy and HSCT for those whose disease responds to the salvage therapy and are eligible for transplant. (yahoo.com)
  • Patients with high-grade muscle invasive bladder cancer (NMIBC) receive intravesical therapy with bacillus Calmette-Guérin (BCG) as the well-established standard-of-care. (urotoday.com)
  • However, even with prompt induction of intravesical therapy, approximately 40 % of patients will recur within 2 years. (urotoday.com)
  • For patients who fail BCG, options include radical cystectomy, repeat BCG therapy, or alternative intravesical salvage therapy. (urotoday.com)
  • This report provides the results from the first 24 patients with active zygomycosis who were enrolled in two open-label, nonrandomized, multicentered compassionate trials that evaluated oral posaconazole as salvage therapy for invasive fungal infections. (qxmd.com)
  • Posaconazole appears promising as an oral therapy for zygomycosis in patients who receive required surgery and control their underlying illness. (qxmd.com)
  • Among 45 patients with CRPC treated with docetaxel (70-75 mg/m2) every 3 to 4 weeks at Hamamatsu University Hospital from January 2004 to July 2012, 19 patients underwent salvage treatments . (bvsalud.org)
  • The reasons why 14 patients moved to salvage treatments after DTX were progressive disease in 12 patients and adverse events in 2. (bvsalud.org)
  • All salvage treatments without grade 4 toxicities described in this study may be acceptable in the patients with CRPC progressing after docetaxel although the effect would be limited. (bvsalud.org)
  • The best management strategy for HIV patients who fail to respond to first-line therapy for Pneumocystis jirovecii pneumonia is currently unclear. (nih.gov)
  • The researchers performed a single-center retrospective analysis of RRMM patients who received any BCMA CAR-T therapy between January 2017 and June 2022, including patients treated in clinical trials and those who received standard-of-care idecabtagene vicleucel or ciltacabtagene autoleucel. (ucsf.edu)
  • Despite achieving a deep hematologic response after therapy, systemic light-chain amyloidosis (AL) patients may not attain an organ response, possibly due to a persistent plasma cell clone below the detection threshold of traditional serological methods. (ucsf.edu)
  • 16. High rate of long-term survival for high-risk lymphoma patients treated with hematopoietic stem cell transplantation as consolidation or salvage therapy. (nih.gov)
  • Patients were stratified by investigational site and primary therapy. (urologytimes.com)
  • It is unclear if inhaled corticosteroid (ICS) therapy can reduce all-cause mortality in patients or subgroups of patients with COPD. (chestnet.org)
  • They found that ICSs, particularly when included as triple therapy, were associated with a reduction in all-cause mortality among patients with COPD (OR 0.73). (chestnet.org)
  • This marks the approval of our third indication in Europe for our CAR T cell therapy portfolio, underscoring our continued drive to deliver the promise of cell therapy with curative potential for more patients. (yahoo.com)
  • With Breyanzi, the majority (73.9%) of patients achieved a CR compared to less than half (43.5%) of those who were treated with standard therapy. (yahoo.com)
  • Patients resistant to a cisplatin-based combination may receive VAC or paclitaxel/gemcitabine or gemcitabine/oxaliplatin as salvage therapy. (medscape.com)
  • A 73.2% of patients benefited from targeted therapy. (who.int)
  • The mean total costs of drugs was $22 256 in patients with standard therapy alone whereas the cost increased to $80 396 after the addition of targeted therapy. (who.int)
  • This study is the first to show the clinical effectiveness and costs of targeted therapy in patients with metastatic colorectal cancer. (who.int)
  • Salvage partial gland ablation (sPGA) has been proposed to treat some localized radiorecurrent prostate cancer. (nih.gov)
  • There has been a lot of conversation about the role of and the use of multi-parametric MRIs in the initial diagnostic stages of prostate cancer, but little is known about its potential clinical application in the use of early salvage radiotherapy after failed radical prostatectomy. (malecare.org)
  • It would be of great advantage to us if we were able to improve the early detection of responders to salvage external beam radiotherapy (RT) after failed radical prostatectomy (RP). (malecare.org)
  • Subgroup analysis of those who had PD after BCMA CAR-T was performed to assess overall survival (OS) from time of PD and types of salvage regimens utilized including ORR and treatment duration for subsequent line therapies. (ucsf.edu)
  • The median age and serum prostate-specific antigen (PSA) level at starting salvage treatments was 71 years (range 45 to 79) and 241.1 ng/mL (range 3.06 to 1,643.0), respectively. (bvsalud.org)
  • All pts relapsed after a median of 2 (range 1-4) prior therapies and all (100%) pts received prior anthracycline. (confex.com)
  • Results of the primary analysis, with a median follow-up of 17.5 months were consistent with the interim analysis, with median EFS not reached for Breyanzi (95% CI: 9.5-NR) vs. 2.4 months for standard therapy (95% CI: 2.2-4.9). (yahoo.com)
  • 8. High-dose therapy and autologous stem cell transplantation for follicular lymphoma undergoing transformation to diffuse large B-cell lymphoma. (nih.gov)
  • Starting with our Asthma content area, controlled studies showing the outcomes of extracorporeal membrane oxygenation (ECMO) as salvage therapy for asthma exacerbations with respiratory failure have not been performed. (chestnet.org)
  • It is essential to direct efforts in patient-caregiver education to allow early recognition and management of all diabetic foot problems and to build integrated pathways of care that facilitate timely access to limb salvage procedures. (japmaonline.org)
  • BM with evidence of persistent leukemia 5-10% blasts post induction/salvage therapy. (nih.gov)
  • At that time, therapy was interrupted due to the worsening of neutropenia. (biomedcentral.com)
  • To evaluate the ability of MRI and prostate biopsy characteristics to identify an index lesion suitable for sPGA and validate this selection using detailed tumor maps created from whole-mount slides from salvage radical prostatectomy (sRP) specimens. (nih.gov)
  • Larger, prospective studies are required to evaluate both the role of MRI and clinical criteria in guiding focal salvage therapy and the effectiveness of this modality for radiorecurrent prostate cancer. (nih.gov)
  • For metastatic colorectal cancer a series of novel therapies has emerged during the last decade but their use in routine clinical practice and their costs are not well documented. (who.int)
  • Salvage treatments include DTX (30 mg/m2) + cisplatin (CDDP) (70 mg/m2)/ carboplatin (Area under the curve = 4), etoposide + CDDP, paclitaxel + CDDP, cyclophosphamide , S-l, tegaful- uracil . (bvsalud.org)
  • Finally, they can lead to early detection of recurrence, and timely implementation of salvage therapy. (roswellpark.org)
  • In this issue, Chen and colleagues report the results of a systematic review and meta-analysis to determine if inhaled therapy containing ICSs reduces all-cause mortality. (chestnet.org)
  • In this highly treatment-experienced population, zidovudine as part of a salvage regimen appeared effective. (nih.gov)
  • 7. Relapse in common lymphoma subtypes: salvage treatment options for follicular lymphoma, diffuse large cell lymphoma and Hodgkin disease. (nih.gov)
  • What must be developed is a type of "salvage therapy" that has the potential to reverse, or at least dramatically lessen, the aggressive natural history of silicosis that develops over relatively short time periods. (cdc.gov)
  • Limb salvage efforts may include aggressive therapy such as revascularization procedures and advanced wound-healing modalities. (japmaonline.org)
  • That was likely confounding the results given that we now have more effective salvage therapies. (ecancer.org)
  • In this issue we feature the first part of the lecture by Heiko Schöder, MD, MBA, Chief of the Molecular Imaging and Therapy Service in the Department of Radiology at Memorial Sloan Kettering Cancer Center and professor of radiology at Weill Cornell Medical College (both in New York, NY), who spoke on oncology and therapy topics at the meeting. (snmjournals.org)
  • Standard therapy to control graft rejection generally involves a combination of corticosteroids, a calcineurin inhibitor (cyclosporine or tacrolimus), and an antiproliferative agent. (medscape.com)
  • Targeted therapy associated to standard therapy is highly prevalent in Lebanon in metastatic disease and the associated medical cost substantial. (who.int)
  • The objective of this study was to describe the efficacy of zidovudine as modern day salvage antiretroviral therapy. (nih.gov)
  • Liver transplantation has become accepted therapy for several causes of irreversible liver disease. (medscape.com)
  • Application and success of orthotopic liver transplantation (OLT) has continued to grow, and liver transplantation has become accepted therapy for several causes of irreversible liver disease. (medscape.com)
  • Human Cytomegalovirus (HCMV) still represents a crucial concern in solid organ transplant recipients (SOTRs) and the use of antiviral therapy are limited by side effects and the selection of viral mutations conferring antiviral drug resistance. (biomedcentral.com)
  • This may indicate a general trend, part of the growing interest in nuclear medicine therapies that will be reflected in this lecture. (snmjournals.org)

No images available that match "salvage therapy"